{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:37:24Z","timestamp":1793813844611,"version":"4.6.1"},"reference-count":392,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postdoctoral Fellowship Program and the China Postdoctoral Science Foundation","award":["BX20240085"],"award-info":[{"award-number":["BX20240085"]}]},{"name":"Clinical Cohort Shanghai","award":["SHDC2025CCS018"],"award-info":[{"award-number":["SHDC2025CCS018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-026-01839-x","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:22:48Z","timestamp":1787768568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Current and future therapies for triple-negative breast cancer"],"prefix":"10.1186","volume":"19","author":[{"given":"Zi-Xun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Xiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ling","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Yang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Zhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"1839_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin"},{"key":"1839_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin JL, Sun LP, Munoz D, et al. Analysis of breast cancer mortality in the US-1975 to 2019. JAMA. 2024;331:233\u201341.","journal-title":"JAMA"},{"key":"1839_CR3","doi-asserted-by":"crossref","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clinicians.2024;74:477\u2013495.","DOI":"10.3322\/caac.21863"},{"key":"1839_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim AM, Kwon JE, Ali T, Jang J, Ullah I, Lee YG, et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol. 2023;212:115545.","journal-title":"Biochem Pharmacol"},{"key":"1839_CR5","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"1839_CR6","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","volume":"389","author":"C Denkert","year":"2017","unstructured":"Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430\u201342.","journal-title":"Lancet"},{"key":"1839_CR7","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","volume":"121","author":"BD Lehmann","year":"2011","unstructured":"Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750\u201367.","journal-title":"J Clin Invest"},{"key":"1839_CR8","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","volume":"21","author":"MD Burstein","year":"2015","unstructured":"Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clinical Cancer Res Off J Am Association Cancer Res. 2015;21:1688\u201398.","journal-title":"Clinical Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR9","doi-asserted-by":"publisher","first-page":"1095839","DOI":"10.3389\/fgene.2022.1095839","volume":"13","author":"S Loizides","year":"2022","unstructured":"Loizides S, Constantinidou A. Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy. Front Genet. 2022;13:1095839.","journal-title":"Front Genet"},{"key":"1839_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-018-0850-9","volume":"17","author":"Y Shi","year":"2018","unstructured":"Shi Y, Jin J, Ji W, Guan X. Therapeutic landscape in mutational triple negative breast cancer. Mol Cancer. 2018;17:99.","journal-title":"Mol Cancer"},{"key":"1839_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann BD, Jovanovi\u0107 B, Chen X, Estrada MV, Johnson KN, Shyr Y, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11:e0157368.","journal-title":"PLoS ONE"},{"key":"1839_CR12","doi-asserted-by":"publisher","first-page":"6276","DOI":"10.1038\/s41467-021-26502-6","volume":"12","author":"BD Lehmann","year":"2021","unstructured":"Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, et al. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nat Commun. 2021;12:6276.","journal-title":"Nat Commun"},{"key":"1839_CR13","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12:5668.","journal-title":"Nat Commun"},{"key":"1839_CR14","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1172\/JCI96313","volume":"129","author":"T Gruosso","year":"2019","unstructured":"Gruosso T, Gigoux M, Manem VSK, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Investig. 2019;129:1785\u2013800.","journal-title":"J Clin Investig"},{"key":"1839_CR15","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30:R921-r925.","journal-title":"Curr Biol"},{"key":"1839_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107205","volume":"204","author":"L Zhou","year":"2024","unstructured":"Zhou L, Yu CW. Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment. Pharmacol Res. 2024;204:107205.","journal-title":"Pharmacol Res"},{"key":"1839_CR17","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","volume":"25","author":"P Altea-Manzano","year":"2025","unstructured":"Altea-Manzano P, Decker-Farrell A, Janowitz T, Erez A. Metabolic interplays between the tumour and the host shape the tumour macroenvironment. Nat Rev Cancer. 2025;25:274\u201392.","journal-title":"Nat Rev Cancer"},{"key":"1839_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41392-025-02159-1","volume":"10","author":"B Cui","year":"2025","unstructured":"Cui B, Luo H, He B, et al. Gut dysbiosis conveys psychological stress to activate LRP5\/\u03b2-catenin pathway promoting cancer stemness. Signal Transduct Target Ther. 2025;10:79.","journal-title":"Signal Transduct Target Ther"},{"key":"1839_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41817-2","volume":"14","author":"L Ye","year":"2023","unstructured":"Ye L, Hou Y, Hu W, Wang H, Yang R, Zhang Q, et al. Repressed Blautia-acetate immunological axis underlies breast cancer progression promoted by chronic stress. Nat Commun. 2023;14:6160.","journal-title":"Nat Commun"},{"key":"1839_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ccell.2024.01.013","volume":"42","author":"XY He","year":"2024","unstructured":"He XY, Gao Y, Ng D, et al. Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment. Cancer Cell. 2024;42:474-486.e412.","journal-title":"Cancer Cell"},{"key":"1839_CR21","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41556-025-01667-0","volume":"27","author":"Z Chen","year":"2025","unstructured":"Chen Z, Zhou Y, Xue C, et al. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Nat Cell Biol. 2025;27:1035\u201347.","journal-title":"Nat Cell Biol"},{"key":"1839_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13\u201321.","journal-title":"J Clin Oncol"},{"key":"1839_CR23","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/annonc\/mdy460","volume":"29","author":"S Loibl","year":"2018","unstructured":"Loibl S, Weber KE, Timms KM, et al. Survival analysis of carboplatin added to an anthracycline\/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018;29:2341\u20137.","journal-title":"Ann Oncol"},{"key":"1839_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O\u2019Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19:497\u2013509.","journal-title":"Lancet Oncol"},{"key":"1839_CR25","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1158\/1078-0432.CCR-25-0289","volume":"31","author":"D Jiao","year":"2025","unstructured":"Jiao D, Qiao J, Sun X, et al. Application of neoadjuvant docetaxel plus cisplatin in early-stage triple-negative breast cancer (HELEN-001): results from a phase II trial. Clinical Cancer Res Off J Am Association Cancer Res. 2025;31:2589\u201398.","journal-title":"Clinical Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO-25-01023","volume":"44","author":"S Gupta","year":"2026","unstructured":"Gupta S, Nair N, Hawaldar RW, Joshi S, Gulia S, Shet T, et al. Addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer: a phase III randomized controlled trial. J Clin Oncol. 2026;44:9\u201319.","journal-title":"J Clin Oncol"},{"key":"1839_CR27","doi-asserted-by":"crossref","unstructured":"Kim GM, Jeung H-C, Jung KH, Kim SH, Kim HJ, Lee KH, Park KH, Lee JE, Ahn MS, Kohn S, PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer. American Soc Clin Oncol. 2017","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS587"},{"key":"1839_CR28","doi-asserted-by":"publisher","first-page":"RF2","DOI":"10.1158\/1557-3265.SABCS25-RF2-02","volume":"32","author":"B Felsheim","year":"2026","unstructured":"Felsheim B, Nekljudova V, Carey L, Huober J, Schneeweiss A, Tolaney S, et al. Abstract RF2-02: pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer. Clin Cancer Res. 2026;32:RF2.","journal-title":"Clin Cancer Res"},{"key":"1839_CR29","doi-asserted-by":"crossref","unstructured":"Valero V, Tang G, Rastogi P, Geyer Jr CE, Colangelo LH, Kengla AT, Irvin Jr WJ, Socoteanu MP, Abraham J, Esparaz BT. NRG-BR003: A randomized phase III trial comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative TNBC. Am Soc Clin Oncol. 2025","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA509"},{"key":"1839_CR30","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","volume":"6","author":"KD Yu","year":"2020","unstructured":"Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1390\u20136.","journal-title":"JAMA Oncol"},{"key":"1839_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085457","volume":"391","author":"Y Liu","year":"2025","unstructured":"Liu Y, Gong Y, Zhu XZ, Liu GY, Yu KD, Yang F, et al. Effect of adjuvant carboplatin intensified chemotherapy versus standard chemotherapy on survival in women with high risk, early stage, triple negative breast cancer (CITRINE): randomised, open label phase 3 trial. BMJ. 2025;391:e085457.","journal-title":"BMJ"},{"key":"1839_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/JCO-25-02412","volume":"44","author":"X Chen","year":"2026","unstructured":"Chen X, Huang J, Shi H, et al. Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin in early-stage triple-negative breast cancer (RJBC 1501): a randomized phase III trial. J Clin Oncol. 2026;44:143\u201352.","journal-title":"J Clin Oncol"},{"key":"1839_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24:628\u201337.","journal-title":"Nat Med"},{"key":"1839_CR34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, et al. OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30:558\u201366.","journal-title":"Ann Oncol"},{"key":"1839_CR35","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523\u201333.","journal-title":"N Engl J Med"},{"key":"1839_CR36","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","volume":"22","author":"ML Telli","year":"2016","unstructured":"Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res. 2016;22:3764\u201373.","journal-title":"Clin Cancer Res"},{"key":"1839_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00337","volume":"7","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, et al. Impact of homologous recombination deficiency on outcomes in patients with triple-negative breast cancer treated with carboplatin-based neoadjuvant chemotherapy: secondary analysis of the NeoCART randomized clinical trial. JCO Precis Oncol. 2023;7:e2200337.","journal-title":"JCO Precis Oncol"},{"key":"1839_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102193","volume":"6","author":"L Zhang","year":"2025","unstructured":"Zhang L, Yang L, Ge Y, Zhu Z, Chen B, Yang C, et al. Neoadjuvant anlotinib\/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): phase 2 trial. Cell Rep Med. 2025;6:102193.","journal-title":"Cell Rep Med"},{"issue":"11","key":"1839_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010058","volume":"12","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, Slomba RT, Janes C, et al. Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Immunother Cancer. 2024;12(11):e010058.","journal-title":"J Immunother Cancer"},{"key":"1839_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010294","author":"HD Bear","year":"2025","unstructured":"Bear HD, Deng X, Bandyopadhyay D, Idowu M, Jenkins TM, Kmieciak M, et al. T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-010294.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"1839_CR41","doi-asserted-by":"publisher","first-page":"e91737","DOI":"10.7554\/eLife.91737","volume":"22","author":"G Chen","year":"2023","unstructured":"Chen G, Gu X, Xue J, Zhang X, Yu X, Zhang Y, et al. Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study. Elife. 2023;22(12):e91737.","journal-title":"Elife"},{"key":"1839_CR42","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1158\/2767-9764.CRC-23-0145","volume":"3","author":"VP Nguyen","year":"2023","unstructured":"Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, et al. A pilot study of neoadjuvant nivolumab, ipilimumab, and intralesional oncolytic virotherapy for HER2-negative breast cancer. Cancer Res Commun. 2023;3:1628\u201337.","journal-title":"Cancer Res Commun"},{"key":"1839_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10:227\u201335.","journal-title":"JAMA Oncol"},{"key":"1839_CR44","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Pond\u00e9 NF, La Valle G, Del Mastro L, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497\u2013508.","journal-title":"Ann Oncol"},{"key":"1839_CR45","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147\u201359.","journal-title":"N Engl J Med"},{"key":"1839_CR46","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50\u20138.","journal-title":"JAMA"},{"key":"1839_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jama.2020.23371","volume":"325","author":"HA Parsons","year":"2021","unstructured":"Parsons HA, Burstein HJ. Adjuvant capecitabine in triple-negative breast cancer: new strategies for tailoring treatment recommendations. JAMA. 2021;325:36\u20138.","journal-title":"JAMA"},{"key":"1839_CR48","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(25)00523-6","volume":"26","author":"H Li","year":"2025","unstructured":"Li H, Liu J, Ouyang Q, et al. Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1\/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial. Lancet Oncol. 2025;26:1563\u201374.","journal-title":"Lancet Oncol"},{"key":"1839_CR49","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","volume":"393","author":"J Cort\u00e9s","year":"2025","unstructured":"Cort\u00e9s J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, et al. Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med. 2025;393:1912\u201325.","journal-title":"N Engl J Med"},{"key":"1839_CR50","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","volume":"394","author":"SM Tolaney","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K, et al. Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med. 2026;394:354\u201366.","journal-title":"N Engl J Med"},{"key":"1839_CR51","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","volume":"31","author":"Y Yin","year":"2025","unstructured":"Yin Y, Fan Y, Ouyang Q, Song L, Wang X, Li W, et al. Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2025;31:1969\u201375.","journal-title":"Nat Med"},{"key":"1839_CR52","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42:2281\u201394.","journal-title":"J Clin Oncol"},{"key":"1839_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"1839_CR54","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1038\/s41591-025-03734-3","volume":"31","author":"M Gion","year":"2025","unstructured":"Gion M, Blancas I, Cortez-Castedo P, et al. Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial. Nat Med. 2025;31:2746\u201354.","journal-title":"Nat Med"},{"key":"1839_CR55","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1038\/s41467-020-18194-1","volume":"11","author":"C Vernieri","year":"2020","unstructured":"Vernieri C, Ligorio F, Zattarin E, Rivoltini L, de Braud F. Fasting-mimicking diet plus chemotherapy in breast cancer treatment. Nat Commun. 2020;11:4274.","journal-title":"Nat Commun"},{"key":"1839_CR56","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","volume":"25","author":"L Fan","year":"2024","unstructured":"Fan L, Wang ZH, Ma LX, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol. 2024;25:184\u201397.","journal-title":"Lancet Oncol"},{"key":"1839_CR57","volume-title":"GLORIA: phase III, open-label study of adagloxad simolenin\/OBI-821 in patients with high-risk triple-negative breast cancer, Future oncology","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Cortes J, Barrios CH, Cabrera P, Xu B, Huang CS, et al. GLORIA: phase III, open-label study of adagloxad simolenin\/OBI-821 in patients with high-risk triple-negative breast cancer, Future oncology. London: England; 2022."},{"key":"1839_CR58","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","volume":"36","author":"PF Conte","year":"2025","unstructured":"Conte PF, Dieci MV, Bisagni G, et al. A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. Annals Oncol Off J Eur Soc Med Oncol. 2025;36:1492\u2013502.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR59","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jama.2024.26886","volume":"333","author":"M Ignatiadis","year":"2025","unstructured":"Ignatiadis M, Bailey A, McArthur H, et al. Adjuvant atezolizumab for early triple-negative breast cancer: The ALEXANDRA\/IMpassion030 randomized clinical trial. Jama. 2025;333:1150\u201360.","journal-title":"Jama"},{"key":"1839_CR60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast (Edinburgh, Scotland). 2022;66:169\u201377.","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"1","key":"1839_CR61","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3233\/BD-220052","volume":"42","author":"F Afzal","year":"2023","unstructured":"Afzal F, Aiman W, Zahoor H, Bajwa AR, Kazmi SH, Anwar A, et al. Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials. Breast Dis. 2023;42(1):121\u201336.","journal-title":"Breast Dis"},{"key":"1839_CR62","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1002\/cncr.30789","volume":"123","author":"AJ Ocean","year":"2017","unstructured":"Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123:3843\u201354.","journal-title":"Cancer"},{"key":"1839_CR63","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Tolaney SM, Punie K, et al. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Annals Oncol Off J Eur Soc Med Oncol. 2021;32:1148\u201356.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR64","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341.","journal-title":"N Engl J Med"},{"key":"1839_CR65","unstructured":"U.S.F.a.D. Administration. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer, U.S. Food and Drug Administration, Silver Spring, MD. 2026."},{"key":"1839_CR66","doi-asserted-by":"crossref","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, Wildiers H, Pierga JY. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. New Engl J Med. 2024","DOI":"10.1056\/NEJMoa2407086"},{"key":"1839_CR67","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097\u2013108.","journal-title":"Clin Cancer Res"},{"key":"1839_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102865","volume":"132","author":"F Schettini","year":"2025","unstructured":"Schettini F, Nucera S, Pascual T, et al. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis. Cancer Treat Rev. 2025;132:102865.","journal-title":"Cancer Treat Rev"},{"key":"1839_CR69","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7239","author":"AI Fernandez","year":"2022","unstructured":"Fernandez AI, Liu M, Bellizzi A, Brock J, Fadare O, Hanley K, et al. Examination of low ERBB2 protein expression in breast cancer tissue. JAMA Oncol. 2022. https:\/\/doi.org\/10.1001\/jamaoncol.2021.7239.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1839_CR70","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41523-025-00741-y","volume":"11","author":"Y Bar","year":"2025","unstructured":"Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025;11(1):27.","journal-title":"NPJ Breast Cancer"},{"key":"1839_CR71","doi-asserted-by":"publisher","DOI":"10.1111\/his.15346","author":"E Yang","year":"2025","unstructured":"Yang E, D\u2019Alfonso TM, Morrow M, Brogi E, Wen HY. Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation. Histopathology. 2025. https:\/\/doi.org\/10.1111\/his.15346.","journal-title":"Histopathology"},{"key":"1839_CR72","doi-asserted-by":"crossref","unstructured":"Dacoregio MI, Michelon I, Ernesto do Rego Castro C, Cezar Aquino de Moraes F, Rossato de Almeida G, Ravani LV, Vilbert M, Barros Costa RL. Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis. Breast (Edinburgh, Scotland).2025;79:103853.","DOI":"10.1016\/j.breast.2024.103853"},{"key":"1839_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"},{"key":"1839_CR74","volume":"37","author":"G Gadaleta-Caldarola","year":"2023","unstructured":"Gadaleta-Caldarola G, Lanotte L, Infusino S, Gadaleta-Caldarola A, Schipilliti FM, Citrigno C, et al. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis. Cancer Treat Res Commun. 2023;37:100775.","journal-title":"Cancer Treat Res Commun"},{"key":"1839_CR75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-25-3321","author":"DR Rampa","year":"2026","unstructured":"Rampa DR, Seo M, Ogata N, Yang Z, Sridhar N, Fujii T, et al. Payload diversification overcomes resistance and guides sequential antibody-drug conjugate therapy in breast cancer. Clin Cancer Res. 2026. https:\/\/doi.org\/10.1158\/1078-0432.ccr-25-3321.","journal-title":"Clin Cancer Res"},{"key":"1839_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-026-01181-8","author":"P Schmid","year":"2026","unstructured":"Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, et al. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b\/2 BEGONIA platform trial. Nat Cancer. 2026. https:\/\/doi.org\/10.1038\/s43018-026-01181-8.","journal-title":"Nat Cancer"},{"key":"1839_CR77","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (London, England). 2023;43:297\u2013337.","journal-title":"Cancer Commun (London, England)"},{"key":"1839_CR78","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1158\/1535-7163.MCT-20-0237","volume":"19","author":"EI Graziani","year":"2020","unstructured":"Graziani EI, Sung M, Ma D, et al. PF-06804103, a site-specific anti-HER2 antibody-drug conjugate for the treatment of HER2-expressing breast, gastric, and lung cancers. Mol Cancer Ther. 2020;19:2068\u201378.","journal-title":"Mol Cancer Ther"},{"key":"1839_CR79","doi-asserted-by":"publisher","first-page":"5550","DOI":"10.1200\/JCO.23.00882","volume":"41","author":"IE Krop","year":"2023","unstructured":"Krop IE, Masuda N, Mukohara T, et al. Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3-directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3-expressing metastatic breast cancer: a multicenter, phase i\/ii trial. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:5550\u201360.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1839_CR80","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S1470-2045(25)00470-X","volume":"26","author":"R Bartsch","year":"2025","unstructured":"Bartsch R, Marhold M, Garde-Noguera J, et al. Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2025;26:1467\u201378.","journal-title":"Lancet Oncol"},{"key":"1839_CR81","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.annonc.2025.04.009","volume":"36","author":"J Zhang","year":"2025","unstructured":"Zhang J, Liu R, Wang S, et al. Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I\/II study. Ann Oncol. 2025;36:934\u201343.","journal-title":"Ann Oncol"},{"key":"1839_CR82","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1056\/NEJMoa1814213","volume":"380","author":"A Bardia","year":"2019","unstructured":"Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741\u201351.","journal-title":"N Engl J Med"},{"key":"1839_CR83","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","volume":"30","author":"A Bardia","year":"2024","unstructured":"Bardia A, Sun S, Thimmiah N, et al. Antibody-drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2024;30:2917\u201324.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR84","doi-asserted-by":"publisher","first-page":"9051","DOI":"10.1200\/JCO.2019.37.15_suppl.9051","volume":"37","author":"JM Sands","year":"2019","unstructured":"Sands JM, Shimizu T, Garon EB, Greenberg J, Guevara FM, Heist RS, et al. First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors. J Clin Oncol. 2019;37:9051\u20139051.","journal-title":"J Clin Oncol"},{"key":"1839_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","volume":"42","author":"B Xu","year":"2024","unstructured":"Xu B, Yin Y, Fan Y, Ouyang Q, Song L, Wang X, et al. Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study. J Clin Oncol. 2024;42:104\u2013104.","journal-title":"J Clin Oncol"},{"key":"1839_CR86","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","volume":"18","author":"Q Ouyang","year":"2025","unstructured":"Ouyang Q, Rodon J, Liang Y, et al. Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. J Hematol Oncol. 2025;18:61.","journal-title":"J Hematol Oncol"},{"key":"1839_CR87","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.annonc.2026.03.008","volume":"37","author":"R Dent","year":"2026","unstructured":"Dent R, Shao Z, Schmid P, et al. Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial. Annals Oncol\u202f: Off J Eur Soc Med Oncol. 2026;37:1066\u201380.","journal-title":"Annals Oncol : Off J Eur Soc Med Oncol"},{"key":"1839_CR88","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang F, Zuo W, Liu X-Y, Gong Y, Shen Y, Liang Q, Di G, Li J, Liu G. Impact of bevacizumab on the efficacy of antibody\u2013drug conjugates as later-line treatment of basal-like immune-suppressed triple-negative breast cancer. Am Soc Clin Oncol. 2026.","DOI":"10.1200\/JCO.2026.44.16_suppl.1020"},{"key":"1839_CR89","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1200\/JCO.2014.56.2959","volume":"33","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, et al. EMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. J Clin Oncol. 2015;33:1609\u201319.","journal-title":"J Clin Oncol"},{"key":"1839_CR90","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1158\/2767-9764.CRC-25-0019","volume":"5","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam F, Gutierrez M, Sanz-Garcia E, Villa D, Zhang J, Friedmann J, et al. Phase 2 study of Zilovertamab Vedotin in participants with metastatic solid tumors. Cancer Res Commun. 2025;5:1664\u201373.","journal-title":"Cancer Res Commun"},{"key":"1839_CR91","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","volume":"14","author":"SB Kim","year":"2019","unstructured":"Kim SB, Meric-Bernstam F, Kalyan A, Babich A, Liu R, Tanigawa T, et al. First-in-human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer. Target Oncol. 2019;14:591\u2013601.","journal-title":"Target Oncol"},{"key":"1839_CR92","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/ijc.32154","volume":"145","author":"I Garrido-Laguna","year":"2019","unstructured":"Garrido-Laguna I, Krop I, Burris HA 3rd, Hamilton E, Braiteh F, Weise AM, et al. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019;145:1798\u2013808.","journal-title":"Int J Cancer"},{"key":"1839_CR93","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009;461:1071\u20138.","journal-title":"Nature"},{"key":"1839_CR94","first-page":"1082","volume":"17","author":"AM Gonzalez-Angulo","year":"2011","unstructured":"Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res Off J Am Association Can Res. 2011;17:1082\u20139.","journal-title":"Clin Cancer Res Off J Am Association Can Res"},{"key":"1839_CR95","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137.","journal-title":"Nature"},{"key":"1839_CR96","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321.","journal-title":"Nature"},{"key":"1839_CR97","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"J Litton","year":"2020","unstructured":"Litton J, Hurvitz S, Mina L, Rugo H, Lee K-H, Gon\u00e7alves A, et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020;31:1526\u201335.","journal-title":"Ann Oncol"},{"key":"1839_CR98","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.annonc.2020.11.009","volume":"32","author":"HP Eikesdal","year":"2021","unstructured":"Eikesdal HP, Yndestad S, Elzawahry A, et al. Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals Oncol Off J Eur Soc Med Oncol. 2021;32:240\u20139.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR99","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","volume":"24","author":"E Rodler","year":"2023","unstructured":"Rodler E, Sharma P, Barlow WE, et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2023;24:162\u201374.","journal-title":"Lancet Oncol"},{"key":"1839_CR100","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","volume":"629","author":"JE Abraham","year":"2024","unstructured":"Abraham JE, Pinilla K, Dayimu A, Grybowicz L, Demiris N, Harvey C, et al. The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer. Nature. 2024;629:1142\u20138.","journal-title":"Nature"},{"key":"1839_CR101","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","volume":"30","author":"TJ Tan","year":"2024","unstructured":"Tan TJ, Sammons S, Im YH, She L, Mundy K, Bigelow R, et al. Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2024;30:1240\u20137.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR102","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/1078-0432.CCR-25-1818","volume":"32","author":"HS Rugo","year":"2026","unstructured":"Rugo HS, Cescon DW, Robson ME, Im S-A, Dalenc F, Yanez Ruiz E, et al. KEYLYNK-009: pembrolizumab plus olaparib in locally recurrent inoperable or metastatic triple-negative breast cancer after clinical benefit from first-line pembrolizumab plus chemotherapy. Clin Cancer Res. 2026;32:883\u201393.","journal-title":"Clin Cancer Res"},{"key":"1839_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gon\u00e7alves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363.","journal-title":"N Engl J Med"},{"key":"1839_CR104","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394\u2013405.","journal-title":"N Engl J Med"},{"key":"1839_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.742139","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, et al. Efficacy and safety of PARP inhibitors in advanced or metastatic triple-negative breast cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:742139.","journal-title":"Front Oncol"},{"key":"1839_CR106","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.breast.2021.08.009","volume":"60","author":"X Sun","year":"2021","unstructured":"Sun X, Wang X, Zhang J, Zhao Z, Feng X, Liu L, et al. Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review. Breast (Edinburgh, Scotland). 2021;60:26\u201334.","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1839_CR107","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103834","volume":"78","author":"A Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s A, L\u00f3pez-Miranda E, Fern\u00e1ndez-Ortega A, et al. Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1\/2: the NOBROLA phase 2 study. Breast (Edinburgh, Scotland). 2024;78:103834.","journal-title":"Breast (Edinburgh, Scotland)"},{"key":"1839_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000480","volume":"4","author":"B Pellegrino","year":"2019","unstructured":"Pellegrino B, Mateo J, Serra V, Balma\u00f1a J. Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? ESMO Open. 2019;4:e000480.","journal-title":"ESMO Open"},{"issue":"5","key":"1839_CR109","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2020.02.008","volume":"31","author":"AG Waks","year":"2020","unstructured":"Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia JB, et al. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1\/2-mutant metastatic breast cancer. Annals Oncol. 2020;31(5):590\u20138.","journal-title":"Annals Oncol"},{"key":"1839_CR110","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1158\/1078-0432.CCR-16-2174","volume":"23","author":"A Afghahi","year":"2017","unstructured":"Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, et al. Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clin Cancer Res Off J Am Association Cancer Res. 2017;23:3365\u201370.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR111","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nature18325","volume":"535","author":"A Ray Chaudhuri","year":"2016","unstructured":"Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature. 2016;535:382\u20137.","journal-title":"Nature"},{"key":"1839_CR112","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA. 2008;105:17079\u201384.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1839_CR113","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139.","journal-title":"Cancer Res"},{"key":"1839_CR114","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf DM, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39:989-998.e985.","journal-title":"Cancer Cell"},{"key":"1839_CR115","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41416-024-02776-7","volume":"131","author":"R Kristeleit","year":"2024","unstructured":"Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, et al. PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024;131:820\u201331.","journal-title":"Br J Cancer"},{"key":"1839_CR116","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","volume":"29","author":"A Ring","year":"2023","unstructured":"Ring A, Kilburn LS, Pearson A, et al. Olaparib and ceralasertib (AZD6738) in patients with triple-negative advanced breast cancer: results from cohort E of the plasmaMATCH trial (CRUK\/15\/010). Clin Cancer Res. 2023;29:4751\u20139.","journal-title":"Clin Cancer Res"},{"key":"1839_CR117","doi-asserted-by":"publisher","first-page":"S194","DOI":"10.1016\/j.annonc.2022.03.180","volume":"33","author":"A Tutt","year":"2022","unstructured":"Tutt A, Nowecki Z, Szoszkiewicz R, Im SA, Arkenau HT, Armstrong A, et al. 161O VIOLETTE: randomised phase II study of olaparib (ola) + ceralasertib (cer) or adavosertib (ada) vs ola alone in patients (pts) with metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2022;33:S194\u20135.","journal-title":"Ann Oncol"},{"key":"1839_CR118","doi-asserted-by":"crossref","unstructured":"Aftimos PG, Oliveira M, Punie K et al. A phase 1b\/2 study of the BET inhibitor ZEN-3694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1\/2 mutations. J Clin Oncol. 2022; 40: 1023\u20131023.","DOI":"10.1200\/JCO.2022.40.16_suppl.1023"},{"key":"1839_CR119","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","volume":"28","author":"F Batalini","year":"2022","unstructured":"Batalini F, Xiong N, Tayob N, Polak M, Eismann J, Cantley LC, et al. Phase 1b clinical trial with alpelisib plus olaparib for patients with advanced triple-negative breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2022;28:1493\u20139.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR120","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","volume":"49","author":"JF Liu","year":"2013","unstructured":"Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013;49:2972\u20138.","journal-title":"Eur J Cancer"},{"key":"1839_CR121","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1186\/s12916-023-03046-8","volume":"21","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang W, Yin R, Zhang Y, Zhang Y, Zhang K, et al. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis. BMC Med. 2023;21:376.","journal-title":"BMC Med"},{"key":"1839_CR122","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12916-022-02527-6","volume":"20","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Shao B, Tong Z, Ouyang Q, Wang Y, Xu G, et al. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med. 2022;20:321.","journal-title":"BMC Med"},{"key":"1839_CR123","doi-asserted-by":"crossref","unstructured":"Taylor AM, Chan DLH, Tio M, Patil SM, Traina TA, Robson ME, Khasraw M. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer. Cochrane Database Systematic Reviews. 2021;4:Cd011395.","DOI":"10.1002\/14651858.CD011395.pub2"},{"key":"1839_CR124","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203307","author":"B Kamau","year":"2025","unstructured":"Kamau B, Shulimovich M, Samridhi S. The impact of novel therapies on quality-of-life in triple-negative breast cancer: a systematic review of clinical trials. Cancers (Basel). 2025. https:\/\/doi.org\/10.3390\/cancers17203307.","journal-title":"Cancers (Basel)"},{"key":"1839_CR125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41422-020-0375-9","volume":"31","author":"YZ Jiang","year":"2021","unstructured":"Jiang YZ, Liu Y, Xiao Y, Hu X, Jiang L, Zuo WJ, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31:178\u201386.","journal-title":"Cell Res"},{"key":"1839_CR126","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s10549-020-05647-w","volume":"181","author":"A Kawachi","year":"2020","unstructured":"Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib\/eribulin combination therapy. Breast Cancer Res Treat. 2020;181:323\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR127","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41523-025-00809-9","volume":"11","author":"N Mugo","year":"2025","unstructured":"Mugo N, Contino G. Genomic landscapes of breast cancer in African populations: a systematic review. NPJ Breast Cancer. 2025;11:91.","journal-title":"NPJ Breast Cancer"},{"key":"1839_CR128","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2021.07.037","volume":"157","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Marra A, Morganti S, Zagami P, Gandini S, Esposito A, et al. Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials. Eur J Cancer. 2021;157:40\u20139.","journal-title":"Eur J Cancer"},{"key":"1839_CR129","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1177\/1087057114522690","volume":"19","author":"S Jaeger","year":"2014","unstructured":"Jaeger S, Min J, Nigsch F, Camargo M, Hutz J, Cornett A, et al. Causal network models for predicting compound targets and driving pathways in cancer. J Biomol Screen. 2014;19:791\u2013802.","journal-title":"J Biomol Screen"},{"issue":"7418","key":"1839_CR130","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370. https:\/\/doi.org\/10.1038\/nature11412","journal-title":"Nature"},{"key":"1839_CR131","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1001\/jamaoncol.2016.5281","volume":"3","author":"RK Basho","year":"2017","unstructured":"Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K\/AKT\/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mtor inhibition in combination with liposomal doxorubicin and bevacizumab. JAMA Oncol. 2017;3:509\u201315.","journal-title":"JAMA Oncol"},{"key":"1839_CR132","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","volume":"85","author":"AW Tolcher","year":"2020","unstructured":"Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020;85:673\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1839_CR133","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1200\/JCO.19.00368","volume":"38","author":"P Schmid","year":"2020","unstructured":"Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial. J Clin Oncol. 2020;38:423\u201333.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1839_CR134","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.annonc.2025.12.012","volume":"37","author":"P Schmid","year":"2026","unstructured":"Schmid P, McArthur HL, Cort\u00e9s J et al. Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: results from the randomised, global phase III CAPItello-290 trial. Ann Oncol. 2026;37(5):650\u2013662. https:\/\/doi.org\/10.1016\/j.annonc.2025.12.012","journal-title":"Ann Oncol"},{"key":"1839_CR135","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/S1470-2045(17)30450-3","volume":"18","author":"SB Kim","year":"2017","unstructured":"Kim SB, Dent R, Im SA, Espi\u00e9 M, Blau S, Tan AR, et al. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2017;18:1360\u201372.","journal-title":"Lancet Oncol"},{"key":"1839_CR136","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1158\/1078-0432.CCR-24-0465","volume":"30","author":"RA Dent","year":"2024","unstructured":"Dent RA, Kim SB, Oliveira M, Barrios C, O\u2019Shaughnessy J, Isakoff SJ, et al. Ipatasertib plus paclitaxel for patients with PIK3CA\/AKT1\/PTEN-altered locally advanced unresectable or metastatic triple-negative breast cancer in the ipatunity130 phase III trial. Clin Cancer Res Off J Am Association Cancer Res. 2024;30:4329\u201338.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR137","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/annonc\/mdz177","volume":"30","author":"M Oliveira","year":"2019","unstructured":"Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos-Coelho JL, et al. FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer. Ann Oncol. 2019;30:1289\u201397.","journal-title":"Ann Oncol"},{"key":"1839_CR138","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.CCR-21-2498","volume":"28","author":"Z Shi","year":"2022","unstructured":"Shi Z, Wulfkuhle J, Nowicka M, et al. Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer. Clin Cancer Res. 2022;28:993\u20131003.","journal-title":"Clin Cancer Res"},{"key":"1839_CR139","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1158\/2159-8290.CD-21-1696","volume":"12","author":"P Savas","year":"2022","unstructured":"Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, et al. Alpelisib monotherapy for PI3K-altered, pretreated advanced breast cancer: a phase II study. Cancer Discov. 2022;12:2058\u201373.","journal-title":"Cancer Discov"},{"key":"1839_CR140","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-16-3055","volume":"23","author":"B Jovanovi\u0107","year":"2017","unstructured":"Jovanovi\u0107 B, Mayer IA, Mayer EL, et al. A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II\/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67. Clin Cancer Res. 2017;23:4035\u201345.","journal-title":"Clin Cancer Res"},{"key":"1839_CR141","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamaoncol.2020.6741","volume":"7","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, et al. Effect of capivasertib in patients with an AKT1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial. JAMA Oncol. 2021;7:271\u20138.","journal-title":"JAMA Oncol"},{"key":"1839_CR142","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","volume":"21","author":"Y Xing","year":"2019","unstructured":"Xing Y, Lin NU, Maurer MA, et al. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation. Breast Cancer Res\u202f: BCR. 2019;21:78.","journal-title":"Breast Cancer Res : BCR"},{"key":"1839_CR143","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10549-024-07551-z","volume":"210","author":"V Prasath","year":"2025","unstructured":"Prasath V, Boutrid H, Wesolowski R, et al. Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795\/uprosertib in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat. 2025;210:179\u201389.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR144","doi-asserted-by":"crossref","unstructured":"Schmid P, Im SA, Armstrong A, Park YH, Chung WP, Nowecki Z, Lord S, Wysocki PJ, Lu YS, Dry H, Karwe V. BEGONIA: Phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)\u2014Initial results from arm 1, d+ paclitaxel (P), and arm 6, d+ trastuzumab deruxtecan (T-DXd). Wolters Kluwer Health. 2021","DOI":"10.1200\/JCO.2021.39.15_suppl.1023"},{"key":"1839_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101595","volume":"5","author":"B Lim","year":"2024","unstructured":"Lim B, Seth S, Yam C, et al. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: trial results and insights into \u201cARness.\u201d Cell Rep Med. 2024;5:101595.","journal-title":"Cell Rep Med"},{"key":"1839_CR146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196909","volume":"13","author":"M Davis","year":"2018","unstructured":"Davis M, Tripathi S, Hughley R, He Q, Bae S, Karanam B, et al. AR negative triple negative or \u201cquadruple negative\u201d breast cancers in African American women have an enriched basal and immune signature. PLoS ONE. 2018;13:e0196909.","journal-title":"PLoS ONE"},{"key":"1839_CR147","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","volume":"36","author":"TA Traina","year":"2018","unstructured":"Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O\u2019Shaughnessy J, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:884\u201390.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1839_CR148","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1634\/theoncologist.2019-0564","volume":"25","author":"Q Lu","year":"2020","unstructured":"Lu Q, Xia W, Lee K, Zhang J, Yuan H, Yuan Z, et al. Bicalutamide plus aromatase inhibitor in patients with estrogen receptor-positive\/androgen receptor-positive advanced breast cancer. Oncologist. 2020;25:21-e15.","journal-title":"Oncologist"},{"key":"1839_CR149","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1158\/1078-0432.CCR-19-2170","volume":"26","author":"BD Lehmann","year":"2020","unstructured":"Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, et al. TBCRC 032 IB\/II multicenter study: molecular insights to ar antagonist and pi3k inhibitor efficacy in patients with ar(+) metastatic triple-negative breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2020;26:2111\u201323.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR150","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/onco.13583","volume":"26","author":"Y Yuan","year":"2021","unstructured":"Yuan Y, Lee JS, Yost SE, Frankel PH, Ruel C, Egelston CA, et al. A phase II clinical trial of pembrolizumab and enobosarm in patients with androgen receptor-positive metastatic triple-negative breast cancer. Oncologist. 2021;26:99-e217.","journal-title":"Oncologist"},{"key":"1839_CR151","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.clbc.2021.10.011","volume":"22","author":"DA Yardley","year":"2022","unstructured":"Yardley DA, Young RR, Adelson KB, Silber AL, Najera JE, Daniel DB, et al. A phase II study evaluating orteronel, an inhibitor of androgen biosynthesis, in patients with androgen receptor (AR)-expressing metastatic breast cancer (MBC). Clin Breast Cancer. 2022;22:269\u201378.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR152","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1634\/theoncologist.2018-0243","volume":"24","author":"E Pietri","year":"2019","unstructured":"Pietri E, Massa I, Bravaccini S, et al. Phase II study of dehydroepiandrosterone in androgen receptor-positive metastatic breast cancer. Oncologist. 2019;24:743-e205.","journal-title":"Oncologist"},{"key":"1839_CR153","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1158\/0008-5472.CAN-11-0362","volume":"71","author":"D Pan","year":"2011","unstructured":"Pan D, Kocherginsky M, Conzen S. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer. Cancer Res. 2011;71:6360\u201370.","journal-title":"Cancer Res"},{"key":"1839_CR154","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1158\/1078-0432.CCR-12-3826","volume":"19","author":"M Skor","year":"2013","unstructured":"Skor M, Wonder E, Kocherginsky M, Goyal A, Hall B, Cai Y, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013;19:6163\u201372.","journal-title":"Clin Cancer Res"},{"key":"1839_CR155","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1200\/JCO.2010.34.5579","volume":"30","author":"LA Carey","year":"2012","unstructured":"Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615\u201323.","journal-title":"J Clin Oncol"},{"key":"1839_CR156","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1080\/15384047.2015.1026481","volume":"16","author":"S Cowherd","year":"2015","unstructured":"Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, et al. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther. 2015;16:678\u201383.","journal-title":"Cancer Biol Ther"},{"key":"1839_CR157","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.clbc.2016.05.006","volume":"16","author":"DA Yardley","year":"2016","unstructured":"Yardley DA, Ward PJ, Daniel BR, Eakle JF, Lamar RE, Lane CM, et al. Panitumumab, gemcitabine, and carboplatin as treatment for women with metastatic triple-negative breast cancer: a sarah cannon research institute phase II trial. Clin Breast Cancer. 2016;16:349\u201355.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR158","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.clbc.2019.08.004","volume":"20","author":"K Fenn","year":"2020","unstructured":"Fenn K, Maurer M, Lee SM, Crew KD, Trivedi MS, Accordino MK, et al. Phase 1 study of erlotinib and metformin in metastatic triple-negative breast cancer. Clin Breast Cancer. 2020;20:80\u20136.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR159","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1158\/2767-9764.CRC-24-0255","volume":"4","author":"C Yam","year":"2024","unstructured":"Yam C, Patel M, Hill HA, et al. Targeting the epidermal growth factor receptor pathway in chemotherapy-resistant triple-negative breast cancer: a phase II study. Cancer Res Commun. 2024;4:2823\u201334.","journal-title":"Cancer Res Commun"},{"key":"1839_CR160","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1038\/s41467-023-40061-y","volume":"14","author":"RC Coombes","year":"2023","unstructured":"Coombes RC, Howell S, Lord SR, et al. Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib. Nat Commun. 2023;14:4444.","journal-title":"Nat Commun"},{"key":"1839_CR161","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1158\/1078-0432.CCR-24-2740","volume":"31","author":"TA Yap","year":"2025","unstructured":"Yap TA, Goldman JW, Vinayak S, Tomova A, Hamilton E, Naito Y, et al. First-in-human phase I\/IIa study of the first-in-class CDK2\/4\/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2025;31:2899\u2013909.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR162","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11523-023-00965-7","volume":"18","author":"TM Bauer","year":"2023","unstructured":"Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, et al. A phase Ib study assessing the safety, tolerability, and efficacy of the first-in-class Wee1 inhibitor adavosertib (AZD1775) as monotherapy in patients with advanced solid tumors. Target Oncol. 2023;18:517\u201330.","journal-title":"Target Oncol"},{"key":"1839_CR163","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2353\/ajpath.2010.100421","volume":"177","author":"S Rodriguez-Acebes","year":"2010","unstructured":"Rodriguez-Acebes S, Proctor I, Loddo M, Wollenschlaeger A, Rashid M, Falzon M, et al. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers. Am J Pathol. 2010;177:2034\u201345.","journal-title":"Am J Pathol"},{"key":"1839_CR164","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-016-3812-1","volume":"157","author":"D Rayson","year":"2016","unstructured":"Rayson D, Lupichuk S, Potvin K, et al. Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Res Treat. 2016;157:109\u201316.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR165","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","volume":"184","author":"JR Diamond","year":"2020","unstructured":"Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O\u2019Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184:53\u201362.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR166","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-021-04245-x","volume":"87","author":"F Lynce","year":"2021","unstructured":"Lynce F, Williams JT, Regan MM, Bunnell CA, Freedman RA, Tolaney SM, et al. Phase I study of JAK1\/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2021;87:673\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1839_CR167","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.clbc.2015.11.003","volume":"16","author":"WW Tan","year":"2016","unstructured":"Tan WW, Allred JB, Moreno-Aspitia A, Northfelt DW, Ingle JN, Goetz MP, et al. Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients. Clin Breast Cancer. 2016;16:82\u20136.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174272","author":"K Mokbel","year":"2023","unstructured":"Mokbel K, Kodresko A, Ghazal H, Mokbel R, Trembley J, Jouhara H. The evolving role of cryosurgery in breast cancer management: a comprehensive review. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15174272.","journal-title":"Cancers (Basel)"},{"key":"1839_CR169","doi-asserted-by":"publisher","first-page":"3788","DOI":"10.1016\/j.apsb.2025.05.006","volume":"15","author":"X Li","year":"2025","unstructured":"Li X, Wu J, Xu R, Qin X, Wang S, Yang W, et al. High intensity forced ultrasound-driven ferroptosis as a strategy for anti-tumor immune priming. Acta pharmaceutica Sinica B. 2025;15:3788\u2013804.","journal-title":"Acta pharmaceutica Sinica B"},{"key":"1839_CR170","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10549-021-06408-z","volume":"191","author":"AY Ho","year":"2022","unstructured":"Ho AY, Tabrizi S, Dunn SA, McArthur HL. Current advances in immune checkpoint inhibitor combinations with radiation therapy or cryotherapy for breast cancer. Breast Cancer Res Treat. 2022;191:229\u201341.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR171","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","volume":"16","author":"JF Dekkers","year":"2021","unstructured":"Dekkers JF, van Vliet EJ, Sachs N, Rosenbluth JM, Kopper O, Rebel HG, et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat Protoc. 2021;16:1936\u201365.","journal-title":"Nat Protoc"},{"key":"1839_CR172","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bioelechem.2016.09.003","volume":"113","author":"I Goswami","year":"2017","unstructured":"Goswami I, Coutermarsh-Ott S, Morrison RG, Allen IC, Davalos RV, Verbridge SS, et al. Irreversible electroporation inhibits pro-cancer inflammatory signaling in triple negative breast cancer cells. Bioelectrochemistry (Amsterdam, Netherlands). 2017;113:42\u201350.","journal-title":"Bioelectrochemistry (Amsterdam, Netherlands)"},{"key":"1839_CR173","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10585-025-10350-5","volume":"42","author":"F Russano","year":"2025","unstructured":"Russano F, Corrado G, Bonadies A, Migliano E, di Giacomo R, Esposito E, et al. Prospective multicentre study of patients with cutaneous metastases from breast cancer treated with electrochemotherapy. Clin Exp Metastasis. 2025;42:32.","journal-title":"Clin Exp Metastasis"},{"key":"1839_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1498942","volume":"15","author":"F Sardela de Miranda","year":"2024","unstructured":"Sardela de Miranda F, Martinez-Marin D, Babcock RL, Castro M, Boligala GP, Khan SY, et al. Cryoablation of primary breast cancer tumors induces a systemic abscopal effect altering TIME (Tumor Immune Microenvironment) in distant tumors. Front Immunol. 2024;15:1498942.","journal-title":"Front Immunol"},{"key":"1839_CR175","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1109\/TUFFC.2023.3326561","volume":"70","author":"T Qi","year":"2023","unstructured":"Qi T, Jing Y, Deng J, Chang J, Sun W, Yang R, et al. Boiling histotripsy using dual-frequency protocol on murine breast tumor model and promotes immune activation. IEEE Trans Ultrason Ferroelectr Freq Control. 2023;70:1773\u201385.","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"key":"1839_CR176","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12\u201327.","journal-title":"Cell"},{"key":"1839_CR177","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49.","journal-title":"Signal Transduct Target Ther"},{"key":"1839_CR178","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10555-023-10146-7","volume":"43","author":"C Thakur","year":"2024","unstructured":"Thakur C, Qiu Y, Pawar A, Chen F. Epigenetic regulation of breast cancer metastasis. Cancer Metastasis Rev. 2024;43:597\u2013619.","journal-title":"Cancer Metastasis Rev"},{"key":"1839_CR179","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-031-66686-5_2","volume":"1465","author":"M Darbandi","year":"2024","unstructured":"Darbandi M, Bado IL. Tumor microenvironment and epigenetic implications in breast cancer progression. Adv Exp Med Biol. 2024;1465:15\u201336.","journal-title":"Adv Exp Med Biol"},{"key":"1839_CR180","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383:650\u201363.","journal-title":"N Engl J Med"},{"key":"1839_CR181","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123403","volume":"363","author":"NMA Nik Amirah Auni","year":"2025","unstructured":"Nik Amirah Auni NMA, Mohd Redzwan N, Fauzi AN, Yahya MM, Wong KK. Hypomethylating agents as emerging therapeutics for triple-negative breast cancer. Life Sci. 2025;363:123403.","journal-title":"Life Sci"},{"key":"1839_CR182","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13046-023-02628-x","volume":"42","author":"A Amaro","year":"2023","unstructured":"Amaro A, Reggiani F, Fenoglio D, Gangemi R, Tosi A, Parodi A, et al. Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. J Exp Clin Cancer Res\u202f: CR. 2023;42:67.","journal-title":"J Exp Clin Cancer Res : CR"},{"key":"1839_CR183","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004495","author":"D Papadatos-Pastos","year":"2022","unstructured":"Papadatos-Pastos D, Yuan W, Pal A, et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-004495.","journal-title":"J Immunother Cancer"},{"key":"1839_CR184","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","volume":"28","author":"K Nepali","year":"2021","unstructured":"Nepali K, Liou JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci. 2021;28:27.","journal-title":"J Biomed Sci"},{"key":"1839_CR185","first-page":"2823","volume":"5","author":"M Wong","year":"2015","unstructured":"Wong M, Polly P, Liu T. The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target. Am J Cancer Res. 2015;5:2823\u201337.","journal-title":"Am J Cancer Res"},{"key":"1839_CR186","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1080\/14737140.2019.1552139","volume":"19","author":"Z Liu","year":"2019","unstructured":"Liu Z, Gao Y, Li X. Cancer epigenetics and the potential of epigenetic drugs for treating solid tumors. Expert Rev Anticancer Ther. 2019;19:139\u201349.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1839_CR187","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, et al. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol. 2022;15:121.","journal-title":"J Hematol Oncol"},{"key":"1839_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.946811","volume":"13","author":"J Feng","year":"2022","unstructured":"Feng J, Meng X. Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: fundamentals and beyond. Front Pharmacol. 2022;13:946811.","journal-title":"Front Pharmacol"},{"key":"1839_CR189","volume":"1877","author":"S Sun","year":"2022","unstructured":"Sun S, Yu F, Xu D, Zheng H, Li M. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy, Biochimica et biophysica acta. Reviews Cancer. 2022;1877:188700.","journal-title":"Reviews Cancer"},{"key":"1839_CR190","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","volume":"13","author":"R Duan","year":"2020","unstructured":"Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020;13:104.","journal-title":"J Hematol Oncol"},{"key":"1839_CR191","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CW. Targeting EZH2 in cancer. Nat Med. 2016;22:128\u201334.","journal-title":"Nat Med"},{"key":"1839_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03313-5","volume":"24","author":"YX Zhao","year":"2024","unstructured":"Zhao YX, Wang H, Zhang SW, Zhang WX, Jiang YZ, Shao ZM. Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy. Cancer Cell Int. 2024;24:131.","journal-title":"Cancer Cell Int"},{"key":"1839_CR193","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s10549-024-07387-7","volume":"207","author":"K Mokhtarpour","year":"2024","unstructured":"Mokhtarpour K, Razi S, Rezaei N. Ferroptosis as a promising targeted therapy for triple negative breast cancer. Breast Cancer Res Treat. 2024;207:497\u2013513.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR194","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-022-01260-0","volume":"15","author":"M Liao","year":"2022","unstructured":"Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B, et al. Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 2022;15:44.","journal-title":"J Hematol Oncol"},{"key":"1839_CR195","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"1839_CR196","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01732-y","volume":"22","author":"J Xie","year":"2023","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22:46.","journal-title":"Mol Cancer"},{"key":"1839_CR197","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/s41571-024-00876-0","volume":"21","author":"D Tang","year":"2024","unstructured":"Tang D, Kroemer G, Kang R. Targeting cuproplasia and cuproptosis in cancer. Nat Rev Clin Oncol. 2024;21:370\u201388.","journal-title":"Nat Rev Clin Oncol"},{"key":"1839_CR198","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.chembiol.2019.01.008","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Tan H, Daniels JD, Zandkarimi F, Liu H, Brown LM, et al. Imidazole ketone erastin induces ferroptosis and slows tumor growth in a mouse lymphoma model. Cell Chem Biol. 2019;26:623-633.e629.","journal-title":"Cell Chem Biol"},{"key":"1839_CR199","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1186\/s12951-021-01058-1","volume":"19","author":"X Yao","year":"2021","unstructured":"Yao X, Xie R, Cao Y, Tang J, Men Y, Peng H, et al. Simvastatin induced ferroptosis for triple-negative breast cancer therapy. J Nanobiotechnol. 2021;19:311.","journal-title":"J Nanobiotechnol"},{"key":"1839_CR200","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.1038\/s41598-021-90527-6","volume":"11","author":"T Alothaim","year":"2021","unstructured":"Alothaim T, Charbonneau M, Tang X. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation. Sci Rep. 2021;11:10956.","journal-title":"Sci Rep"},{"key":"1839_CR201","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/s41598-025-85774-w","volume":"15","author":"J Yuan","year":"2025","unstructured":"Yuan J, Liu C, Jiang C, Liu N, Yang Z, Xing H. RSL3 induces ferroptosis by activating the NF-\u03baB signalling pathway to enhance the chemosensitivity of triple-negative breast cancer cells to paclitaxel. Sci Rep. 2025;15:1654.","journal-title":"Sci Rep"},{"key":"1839_CR202","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41419-023-06042-1","volume":"14","author":"SY Park","year":"2023","unstructured":"Park SY, Jeong KJ, Poire A, Zhang D, Tsang YH, Blucher AS, et al. Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer. Cell Death Dis. 2023;14:532.","journal-title":"Cell Death Dis"},{"key":"1839_CR203","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-025-07865-6","volume":"215","author":"WM Tahaney","year":"2026","unstructured":"Tahaney WM, Lanier A, Qian J, Moyer CL, Nguyen N, Ma Y, et al. Inhibition of GPX4 induces the death of p53-mutant triple-negative breast cancer cells. Breast Cancer Res Treat. 2026;215:49.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR204","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies. Signal Transduct Target Ther. 2024;9:55.","journal-title":"Signal Transduct Target Ther"},{"key":"1839_CR205","doi-asserted-by":"crossref","unstructured":"Talty R, Brooks VT, McGeary MK et al. Lipophilic statins deplete gpx4 to promote ferroptosis and sensitize cancer cells to immune checkpoint blockade. Molecular Cancer Therapeutics. 2025: Of1-of12.","DOI":"10.1158\/1535-7163.32710139"},{"key":"1839_CR206","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41589-018-0031-6","volume":"14","author":"MM Gaschler","year":"2018","unstructured":"Gaschler MM, Andia AA, Liu H, et al. FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol. 2018;14:507\u201315.","journal-title":"Nat Chem Biol"},{"key":"1839_CR207","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41420-023-01772-9","volume":"10","author":"T Daimon","year":"2024","unstructured":"Daimon T, Bhattacharya A, Wang K, Haratake N, Nakashoji A, Ozawa H, et al. MUC1-C is a target of salinomycin in inducing ferroptosis of cancer stem cells. Cell Death Discov. 2024;10:9.","journal-title":"Cell Death Discov"},{"key":"1839_CR208","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41419-023-06262-5","volume":"14","author":"E Cosialls","year":"2023","unstructured":"Cosialls E, Pacreau E, Duruel C, et al. mTOR inhibition suppresses salinomycin-induced ferroptosis in breast cancer stem cells by ironing out mitochondrial dysfunctions. Cell Death Dis. 2023;14:744.","journal-title":"Cell Death Dis"},{"key":"1839_CR209","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.freeradbiomed.2025.12.060","volume":"246","author":"Y Wu","year":"2026","unstructured":"Wu Y, Chen D, Wang X, Song M, Wu J, Wu S, et al. Dihydroartemisinin targets GPX4 to induce autophagy-dependent ferroptosis and reduce radioresistance in triple-negative breast cancer. Free Radical Biol Med. 2026;246:35\u201350.","journal-title":"Free Radical Biol Med"},{"key":"1839_CR210","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics, Biochimica et biophysica acta. Reviews Cancer. 2025;1880:189396.","journal-title":"Reviews Cancer"},{"key":"1839_CR211","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5306\/wjco.v7.i1.122","volume":"7","author":"JP Long","year":"2016","unstructured":"Long JP, Li XN, Zhang F. Targeting metabolism in breast cancer: How far we can go? World J Clin Oncol. 2016;7:122\u201330.","journal-title":"World J Clin Oncol"},{"key":"1839_CR212","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060495","volume":"12","author":"S Liu","year":"2022","unstructured":"Liu S, Li Y, Yuan M, Song Q, Liu M. Correlation between the Warburg effect and progression of triple-negative breast cancer. Front Oncol. 2022;12:1060495.","journal-title":"Front Oncol"},{"key":"1839_CR213","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1061789","volume":"12","author":"A Schreier","year":"2022","unstructured":"Schreier A, Zappasodi R, Serganova I, Brown KA, Demaria S, Andreopoulou E. Facts and perspectives: implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. Front Oncol. 2022;12:1061789.","journal-title":"Front Oncol"},{"key":"1839_CR214","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2021.108366","volume":"787","author":"S Delgir","year":"2021","unstructured":"Delgir S, Bastami M, Ilkhani K, Safi A, Seif F, Alivand MR. The pathways related to glutamine metabolism, glutamine inhibitors and their implication for improving the efficiency of chemotherapy in triple-negative breast cancer. Mutat Res Rev Mutat Res. 2021;787:108366.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"1839_CR215","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wang W. Recent progress in immune evasion mechanisms of triple-negative breast cancer. J Transl Med. 2025;23:1314.","journal-title":"J Transl Med"},{"key":"1839_CR216","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1097\/JS9.0000000000001011","volume":"110","author":"C Zheng","year":"2024","unstructured":"Zheng C, Liu Y, Wang X, Bi Z, Qiu P, Qiao G, et al. Clinical efficacy and biomarker analysis of neoadjuvant camrelizumab plus chemotherapy for early-stage triple-negative breast cancer: a experimental single-arm phase II clinical trial pilot study. Int J Surgery (London, England). 2024;110:1527\u201336.","journal-title":"Int J Surgery (London, England)"},{"key":"1839_CR217","first-page":"736","volume":"2","author":"JM Ghergurovich","year":"2021","unstructured":"Ghergurovich JM, Lang JD, Levin MK, et al. Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer. Med (New York, NY). 2021;2:736\u201354.","journal-title":"Med (New York, N.Y.)"},{"key":"1839_CR218","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj5070","volume":"13","author":"AW Chung","year":"2021","unstructured":"Chung AW, Anand K, Anselme AC, Chan AA, Gupta N, Venta LA, et al. A phase 1\/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021;13:eabj5070.","journal-title":"Sci Transl Med"},{"key":"1839_CR219","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082252","author":"E Varghese","year":"2020","unstructured":"Varghese E, Samuel SM, L\u00ed\u0161kov\u00e1 A, Samec M, Kubatka P, B\u00fcsselberg D. Targeting glucose metabolism to overcome resistance to anticancer chemotherapy in breast cancer. Cancers. 2020. https:\/\/doi.org\/10.3390\/cancers12082252.","journal-title":"Cancers"},{"key":"1839_CR220","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semcancer.2017.01.004","volume":"43","author":"SR Amith","year":"2017","unstructured":"Amith SR, Fliegel L. Na(+)\/H(+) exchanger-mediated hydrogen ion extrusion as a carcinogenic signal in triple-negative breast cancer etiopathogenesis and prospects for its inhibition in therapeutics. Semin Cancer Biol. 2017;43:35\u201341.","journal-title":"Semin Cancer Biol"},{"key":"1839_CR221","first-page":"825","volume":"16","author":"Y Chang","year":"2024","unstructured":"Chang Y, Du R, Xia F, Xu X, Wang H, Chen X. Dysregulation of fatty acid metabolism in breast cancer and its targeted therapy. Breast Cancer (Dove Medical Press). 2024;16:825\u201344.","journal-title":"Breast Cancer (Dove Medical Press)"},{"key":"1839_CR222","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","volume":"133","author":"TM Seibt","year":"2019","unstructured":"Seibt TM, Proneth B, Conrad M. Role of GPX4 in ferroptosis and its pharmacological implication. Free Radical Biol Med. 2019;133:144\u201352.","journal-title":"Free Radical Biol Med"},{"key":"1839_CR223","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med"},{"key":"1839_CR224","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","volume":"31","author":"EA Mittendorf","year":"2025","unstructured":"Mittendorf EA, Assaf ZJ, Harbeck N, et al. Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial. Nat Med. 2025;31:2397\u2013404.","journal-title":"Nat Med"},{"key":"1839_CR225","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","volume":"33","author":"L Gianni","year":"2022","unstructured":"Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Annals Oncol Off J Eur Soc Med Oncol. 2022;33:534\u201343.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR226","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217\u201326.","journal-title":"N Engl J Med"},{"key":"1839_CR227","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med. 2024;30:249\u201356.","journal-title":"Nat Med"},{"key":"1839_CR228","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44\u201359.","journal-title":"Lancet Oncol"},{"key":"1839_CR229","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","volume":"32","author":"D Miles","year":"2021","unstructured":"Miles D, Gligorov J, Andr\u00e9 F, Cameron D, Schneeweiss A, Barrios C, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced\/metastatic triple-negative breast cancer. Annals Oncol Off J Eur Soc Med Oncol. 2021;32:994\u20131004.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR230","first-page":"499","volume":"22","author":"EP Winer","year":"2021","unstructured":"Winer EP, Lipatov O, Im SA, Goncalves A, Mu\u00f1oz-Couselo E, Lee KS, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial, The Lancet. Oncology. 2021;22:499\u2013511.","journal-title":"Oncology"},{"key":"1839_CR231","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","volume":"34","author":"R Nanda","year":"2016","unstructured":"Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:2460\u20137.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1839_CR232","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1093\/annonc\/mdy518","volume":"30","author":"S Adams","year":"2019","unstructured":"Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals Oncol Off J Eur Soc Med Oncol. 2019;30:405\u201311.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR233","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817\u201328.","journal-title":"Lancet"},{"key":"1839_CR234","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"1839_CR235","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","volume":"35","author":"R Dent","year":"2024","unstructured":"Dent R, Andr\u00e9 F, Gon\u00e7alves A, Martin M, Schmid P, Sch\u00fctz F, et al. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer. Ann Oncol. 2024;35:630\u201342.","journal-title":"Ann Oncol"},{"key":"1839_CR236","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.annonc.2022.07.1940","volume":"33","author":"S Loibl","year":"2022","unstructured":"Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022;33:1149\u201358.","journal-title":"Ann Oncol"},{"key":"1839_CR237","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41591-020-01189-2","volume":"27","author":"T Bachelot","year":"2021","unstructured":"Bachelot T, Filleron T, Bieche I, et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial. Nat Med. 2021;27:250\u20135.","journal-title":"Nat Med"},{"key":"1839_CR238","first-page":"569","volume":"31","author":"P Schmid","year":"2020","unstructured":"Schmid P, Salgado R, Park YH, Mu\u00f1oz-Couselo E, Kim SB, Sohn J, et al. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study, Annals of oncology\u202f: official journal of the European Society for. Med Oncol. 2020;31:569\u201381.","journal-title":"Med Oncol"},{"key":"1839_CR239","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41523-024-00626-6","volume":"10","author":"O Amato","year":"2024","unstructured":"Amato O, Giannopoulou N, Ignatiadis M. Circulating tumor DNA validity and potential uses in metastatic breast cancer. NPJ breast cancer. 2024;10:21. https:\/\/doi.org\/10.1038\/s41523-024-00626-6","journal-title":"NPJ breast cancer"},{"key":"1839_CR240","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abl4414","volume":"15","author":"G Thacker","year":"2023","unstructured":"Thacker G, Henry S, Nandi A, Debnath R, Singh S, Nayak A, et al. Immature natural killer cells promote progression of triple-negative breast cancer. Sci Transl Med. 2023;15:eabl4414.","journal-title":"Sci Transl Med"},{"key":"1839_CR241","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009160","author":"BC O\u2019Connell","year":"2024","unstructured":"O\u2019Connell BC, Hubbard C, Zizlsperger N, Fitzgerald D, Kutok JL, Varner J, et al. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/jitc-2024-009160.","journal-title":"J Immunother Cancer"},{"key":"1839_CR242","first-page":"4586","volume":"31","author":"SH Jeon","year":"2025","unstructured":"Jeon SH, Suh KJ, Jung S, et al. Proliferation of tumor-related regulatory t cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer. Clin Cancer Res Off J Am Association Can Res. 2025;31:4586\u201397.","journal-title":"Clin Cancer Res Off J Am Association Can Res"},{"key":"1839_CR243","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","volume":"25","author":"L Voorwerk","year":"2019","unstructured":"Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25:920\u20138.","journal-title":"Nat Med"},{"key":"1839_CR244","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-14-0082","volume":"20","author":"K Pan","year":"2014","unstructured":"Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clin Cancer Res Off J Am Association Cancer Res. 2014;20:3003\u201311.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR245","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discovery. 2011;10:417\u201327.","journal-title":"Nat Rev Drug Discovery"},{"key":"1839_CR246","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"key":"1839_CR247","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41419-017-0061-0","volume":"9","author":"MB Schaaf","year":"2018","unstructured":"Schaaf MB, Garg AD, Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018;9:115.","journal-title":"Cell Death Dis"},{"key":"1839_CR248","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1002\/JLB.5RU0222-082R","volume":"111","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Brekken RA. Direct and indirect regulation of the tumor immune microenvironment by VEGF. J Leukoc Biol. 2022;111:1269\u201386.","journal-title":"J Leukoc Biol"},{"key":"1839_CR249","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm0901-987","volume":"7","author":"RK Jain","year":"2001","unstructured":"Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med. 2001;7:987\u20139.","journal-title":"Nat Med"},{"key":"1839_CR250","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","volume":"91","author":"S Goel","year":"2011","unstructured":"Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071\u2013121.","journal-title":"Physiol Rev"},{"key":"1839_CR251","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","volume":"88","author":"H Wildiers","year":"2003","unstructured":"Wildiers H, Guetens G, De Boeck G, Verbeken E, Landuyt B, Landuyt W, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer. 2003;88:1979\u201386.","journal-title":"Br J Cancer"},{"key":"1839_CR252","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195\u2013203.","journal-title":"Nat Rev Immunol"},{"issue":"Suppl 3","key":"1839_CR253","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000088479","volume":"69","author":"N Ferrara","year":"2005","unstructured":"Ferrara N. VEGF as a therapeutic target in cancer. Oncology. 2005;69(Suppl 3):11\u20136.","journal-title":"Oncology"},{"key":"1839_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"J Garcia","year":"2020","unstructured":"Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"key":"1839_CR255","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011314","author":"M Chen","year":"2025","unstructured":"Chen M, Huang R, Rong Q, Yang W, Shen X, Sun Q, et al. Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011314.","journal-title":"J Immunother Cancer"},{"key":"1839_CR256","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376.","journal-title":"N Engl J Med"},{"key":"1839_CR257","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.clbc.2016.07.005","volume":"16","author":"DA Yardley","year":"2016","unstructured":"Yardley DA, Reeves J, Dees EC, et al. Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II study. Clin Breast Cancer. 2016;16:471-479.e471.","journal-title":"Clin Breast Cancer"},{"key":"1839_CR258","first-page":"2745","volume":"19","author":"LS Schwartzberg","year":"2013","unstructured":"Schwartzberg LS, Tauer KW, Hermann RC, et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin Cancer Res Off J Am Association Can Res. 2013;19:2745\u201354.","journal-title":"Clin Cancer Res Off J Am Association Can Res"},{"key":"1839_CR259","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10549-013-2793-6","volume":"143","author":"M Fan","year":"2014","unstructured":"Fan M, Zhang J, Wang Z, Wang B, Zhang Q, Zheng C, et al. Phosphorylated VEGFR2 and hypertension: potential biomarkers to indicate VEGF-dependency of advanced breast cancer in anti-angiogenic therapy. Breast Cancer Res Treat. 2014;143:141\u201351.","journal-title":"Breast Cancer Res Treat"},{"key":"1839_CR260","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1186\/1471-2407-14-820","volume":"14","author":"X Hu","year":"2014","unstructured":"Hu X, Cao J, Hu W, Wu C, Pan Y, Cai L, et al. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer. BMC Cancer. 2014;14:820.","journal-title":"BMC Cancer"},{"key":"1839_CR261","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1186\/s12885-020-07616-4","volume":"20","author":"YLE Ang","year":"2020","unstructured":"Ang YLE, Ho GF, Soo RA, Sundar R, Tan SH, Yong WP, et al. A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer. 2020;20:1118.","journal-title":"BMC Cancer"},{"key":"1839_CR262","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000696","author":"J Liu","year":"2020","unstructured":"Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2020-000696.","journal-title":"J Immunother Cancer"},{"key":"1839_CR263","doi-asserted-by":"publisher","first-page":"e13127","DOI":"10.1200\/JCO.2024.42.16_suppl.e13127","volume":"42","author":"W Huang","year":"2024","unstructured":"Huang W, Chen Q, Shen Y, Wang C, Huang Z, Liu J, et al. Efficacy and safety of apatinib combined with nab-paclitaxel for second-line treatment of metastatic triple negative breast cancer (TNBC): An open-label phase II trial. J Clin Oncol. 2024;42:e13127\u2013e13127.","journal-title":"J Clin Oncol"},{"key":"1839_CR264","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/ijc.28829","volume":"135","author":"X Hu","year":"2014","unstructured":"Hu X, Zhang J, Xu B, Jiang Z, Ragaz J, Tong Z, et al. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer. Int J Cancer. 2014;135:1961\u20139.","journal-title":"Int J Cancer"},{"key":"1839_CR265","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1620\/tjem.2023.J006","volume":"260","author":"W Fan","year":"2023","unstructured":"Fan W, Ding J, Zhong W. Efficacy and Safety of third-line apatinib plus chemotherapy in metastatic triple-negative breast cancer patients: a multicenter retrospective, cohort study. Tohoku J Exp Med. 2023;260:13\u201320.","journal-title":"Tohoku J Exp Med"},{"key":"1839_CR266","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen L, Jiang YZ, Wu SY, et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin Cancer Res Off J Am Association Cancer Res. 2022;28:2807\u201317.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR267","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"SY Wu","year":"2022","unstructured":"Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, et al. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer. 2022;21:84.","journal-title":"Mol Cancer"},{"key":"1839_CR268","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-025-02505-5","volume":"25","author":"XY Liu","year":"2025","unstructured":"Liu XY, Sui XY, Xu Y, et al. Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial). Mol Cancer. 2025;25:15.","journal-title":"Mol Cancer"},{"key":"1839_CR269","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41392-025-02137-7","volume":"10","author":"G Shen","year":"2025","unstructured":"Shen G, Liu Z, Wang M, et al. Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial. Signal Transduct Target Ther. 2025;10:41.","journal-title":"Signal Transduct Target Ther"},{"key":"1839_CR270","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s13063-020-04342-x","volume":"21","author":"S Wu","year":"2020","unstructured":"Wu S, Zhang L, Li H, Xu J, Jiang C, Sun T. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial. Trials. 2020;21:420.","journal-title":"Trials"},{"key":"1839_CR271","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S1470-2045(13)70335-8","volume":"14","author":"D Cameron","year":"2013","unstructured":"Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol. 2013;14:933\u201342.","journal-title":"Lancet Oncol"},{"key":"1839_CR272","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2023.12.012","volume":"42","author":"SL Shiao","year":"2024","unstructured":"Shiao SL, Gouin KH 3rd, Ing N, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell. 2024;42:70-84.e78.","journal-title":"Cancer Cell"},{"key":"1839_CR273","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559\u201369.","journal-title":"J Clin Oncol"},{"key":"1839_CR274","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41591-018-0078-7","volume":"24","author":"P Savas","year":"2018","unstructured":"Savas P, Virassamy B, Ye C, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. 2018;24:986\u201393.","journal-title":"Nat Med"},{"key":"1839_CR275","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959\u201366.","journal-title":"J Clin Oncol"},{"key":"1839_CR276","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1158\/1538-7445.AM2015-2859","volume":"75","author":"LA Emens","year":"2015","unstructured":"Emens LA, Braiteh FS, Cassier P, Delord JP, Eder JP, Fasso M, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res. 2015;75:2859.","journal-title":"Cancer Res"},{"key":"1839_CR277","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-019-1450-6","volume":"572","author":"MD Wellenstein","year":"2019","unstructured":"Wellenstein MD, Coffelt SB, Duits DEM, et al. Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature. 2019;572:538\u201342.","journal-title":"Nature"},{"key":"1839_CR278","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science (New York, NY). 2018;359:1361\u20135.","journal-title":"Science (New York, N.Y.)"},{"key":"1839_CR279","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023;614:635\u201348.","journal-title":"Nature"},{"key":"1839_CR280","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1158\/1078-0432.CCR-24-2172","volume":"31","author":"CA Jaeger-Ruckstuhl","year":"2025","unstructured":"Jaeger-Ruckstuhl CA, Specht JM, Voutsinas JM, et al. Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies. Clin Cancer Res. 2025;31:503\u201314.","journal-title":"Clin Cancer Res"},{"key":"1839_CR281","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"1839_CR282","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353.","journal-title":"N Engl J Med"},{"key":"1839_CR283","first-page":"1","volume":"43","author":"D Cruceriu","year":"2020","unstructured":"Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I. The dual role of tumor necrosis factor-alpha (TNF-\u03b1) in breast cancer: molecular insights and therapeutic approaches. Cellular oncology (Dordrecht, Netherlands). 2020;43:1\u201318.","journal-title":"Cellular oncology (Dordrecht, Netherlands)"},{"key":"1839_CR284","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/path.6395","volume":"265","author":"X Lu","year":"2025","unstructured":"Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, et al. Extracellular matrix cancer-associated fibroblasts promote stromal fibrosis and immune exclusion in triple-negative breast cancer. J Pathol. 2025;265:385\u201399.","journal-title":"J Pathol"},{"key":"1839_CR285","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, et al. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021;184:5357-5374.e5322.","journal-title":"Cell"},{"key":"1839_CR286","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","volume":"607","author":"C Hong","year":"2022","unstructured":"Hong C, Schubert M, Tijhuis AE, Requesens M, Roorda M, van den Brink A, et al. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature. 2022;607:366\u201373.","journal-title":"Nature"},{"key":"1839_CR287","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1158\/1078-0432.CCR-20-3944","volume":"27","author":"ML Telli","year":"2021","unstructured":"Telli ML, Nagata H, Wapnir I, et al. Intratumoral plasmid IL12 expands CD8(+) T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clin Cancer Res Off J Am Association Cancer Res. 2021;27:2481\u201393.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR288","doi-asserted-by":"publisher","first-page":"5411","DOI":"10.1172\/JCI75661","volume":"124","author":"TU Barbie","year":"2014","unstructured":"Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Investig. 2014;124:5411\u201323.","journal-title":"J Clin Investig"},{"key":"1839_CR289","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-021-06128-4","volume":"186","author":"J Liu","year":"2021","unstructured":"Liu J, Li Y, Li Q, Liang D, Wang Q, Liu Q. Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Can Res Treat. 2021;186:687\u201397.","journal-title":"Breast Can Res Treat"},{"key":"1839_CR290","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li Q, Wang Y, Jia W, Deng H, Li G, Deng W, et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade. Clin Cancer Res Off J Am Association Cancer Res. 2020;26:1712\u201324.","journal-title":"Clin Cancer Res Off J Am Association Cancer Res"},{"key":"1839_CR291","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s40425-019-0680-3","volume":"7","author":"AS Zimmer","year":"2019","unstructured":"Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women\u2019s cancers with biomarker analyses. J Immunother Can. 2019;7:197.","journal-title":"J Immunother Can"},{"key":"1839_CR292","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Goedegebuure SP, Chen MY, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16:131.","journal-title":"Genome Med"},{"issue":"225","key":"1839_CR293","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108679","volume":"1","author":"RC Chick","year":"2021","unstructured":"Chick RC, Clifton GT, Hale DF, Vreeland TJ, Hickerson AT, Bohan PM, et al. Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. Clin Immunol (Orlando, Fla). 2021;1(225):108679.","journal-title":"Clin Immunol (Orlando, Fla.)"},{"key":"1839_CR294","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547:217\u201321.","journal-title":"Nature"},{"key":"1839_CR295","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","volume":"183","author":"DK Wells","year":"2020","unstructured":"Wells DK, van Buuren MM, Dang KK, et al. Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020;183:818-834.e813.","journal-title":"Cell"},{"key":"1839_CR296","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011432","author":"KA Ahmed","year":"2025","unstructured":"Ahmed KA, Kim Y, Kim S, Wang MH, DeJesus M, Arrington JA, et al. Nivolumab and stereotactic radiosurgery for patients with breast cancer brain metastases: long-term results and biomarker analysis from a non-randomized, open-label, phase Ib study. J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/jitc-2024-011432.","journal-title":"J Immunother Cancer"},{"key":"1839_CR297","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s11060-025-05230-7","volume":"175","author":"VM Khatri","year":"2025","unstructured":"Khatri VM, Mestres-Villanueva MA, Daniel S, Yarlagadda S, Doniparthi A, Upadhyay R, et al. Sacituzumab govitecan and stereotactic radiosurgery in the management of HER2 negative breast cancer brain metastases: a multi-institutional report. J Neurooncol. 2025;175:1435\u201341.","journal-title":"J Neurooncol"},{"key":"1839_CR298","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"1839_CR299","first-page":"1241","volume":"27","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence, Annals of oncology\u202f: official journal of the European Society for. Med Oncol. 2016;27:1241\u20138.","journal-title":"Med Oncol"},{"key":"1839_CR300","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli KR, Oberg AL, Keeney GL, Christianson TJ, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008;108:619\u201326.","journal-title":"Gynecol Oncol"},{"key":"1839_CR301","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/cas.14510","volume":"111","author":"U Toh","year":"2020","unstructured":"Toh U, Sakurai S, Saku S, Takao Y, Okabe M, Iwakuma N, et al. Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer. Cancer Sci. 2020;111:2760\u20139.","journal-title":"Cancer Sci"},{"key":"1839_CR302","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41523-022-00486-y","volume":"8","author":"Y Abdou","year":"2022","unstructured":"Abdou Y, Goudarzi A, Yu JX, Upadhaya S, Vincent B, Carey LA. Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. NPJ Breast Cancer. 2022;8:121.","journal-title":"NPJ Breast Cancer"},{"key":"1839_CR303","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205163","author":"JVL Niemi","year":"2022","unstructured":"Niemi JVL, Sokolov AV, Schi\u00f6th HB. Neoantigen vaccines; clinical trials, classes, indications, adjuvants and combinatorial treatments. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14205163.","journal-title":"Cancers (Basel)"},{"key":"1839_CR304","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"1839_CR305","doi-asserted-by":"crossref","unstructured":"Gandhi S, Forsyth PA, Opyrchal M, Ahmed KA, Attwood K, Levine EG, O'Connor TL, Early AP, Fenstermaker RA, Prasad D. Phase IIa study of \u03b1DC1 vaccines targeting HER2\/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. Am Soc Clin Oncol. 2023","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS1112"},{"key":"1839_CR306","doi-asserted-by":"crossref","unstructured":"Gandhi S, Forsyth PA, Opyrchal M, Ahmed KA, Attwood K, Levine EG, O'Connor TL, Early AP, Fenstermaker RA, Prasad D. Phase IIa study of \u03b1DC1 vaccines targeting HER2\/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from breast cancer. Am Soc Clin Oncol. 2025","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2088"},{"key":"1839_CR307","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547:222\u20136.","journal-title":"Nature"},{"key":"1839_CR308","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. MRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"key":"1839_CR309","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010;8:62\u201373.","journal-title":"Nat Rev Microbiol"},{"key":"1839_CR310","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1480811","volume":"15","author":"IM Khan","year":"2024","unstructured":"Khan IM, Nassar N, Chang H, Khan S, Cheng M, Wang Z, et al. The microbiota: a key regulator of health, productivity, and reproductive success in mammals. Front Microbiol. 2024;15:1480811.","journal-title":"Front Microbiol"},{"key":"1839_CR311","first-page":"873","volume":"34","author":"L Yaghjyan","year":"2023","unstructured":"Yaghjyan L, Mai V, Darville LNF, Cline J, Wang X, Ukhanova M, et al. Associations of gut microbiome with endogenous estrogen levels in healthy postmenopausal women. Cancer Causes Control CCC. 2023;34:873\u201381.","journal-title":"Cancer Causes Control CCC"},{"key":"1839_CR312","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1210\/jc.2014-2222","volume":"99","author":"BJ Fuhrman","year":"2014","unstructured":"Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, et al. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99:4632\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"1839_CR313","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111039","volume":"124","author":"Q Shi","year":"2023","unstructured":"Shi Q, Wang J, Zhou M, Zheng R, Zhang X, Liu B. Gut Lactobacillus contribute to the progression of breast cancer by affecting the anti-tumor activities of immune cells in the TME of tumor-bearing mice. Int Immunopharmacol. 2023;124:111039.","journal-title":"Int Immunopharmacol"},{"key":"1839_CR314","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41571-023-00785-8","volume":"20","author":"AM Thomas","year":"2023","unstructured":"Thomas AM, Fidelle M, Routy B, Kroemer G, Wargo JA, Segata N, et al. Gut OncoMicrobiome signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nat Rev Clin Oncol. 2023;20:583\u2013603.","journal-title":"Nat Rev Clin Oncol"},{"key":"1839_CR315","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/1878-0261.13760","volume":"19","author":"A Ullern","year":"2025","unstructured":"Ullern A, Holm K, R\u00f8ssevold AH, Andresen NK, Bang C, Lingj\u00e6rde OC, et al. Gut microbiota diversity is prognostic and associated with benefit from chemo-immunotherapy in metastatic triple-negative breast cancer. Mol Oncol. 2025;19:1229\u201343.","journal-title":"Mol Oncol"},{"key":"1839_CR316","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","volume":"28","author":"AH R\u00f8ssevold","year":"2022","unstructured":"R\u00f8ssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, et al. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28:2573\u201383.","journal-title":"Nat Med"},{"key":"1839_CR317","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37636-0","volume":"14","author":"JD Ransohoff","year":"2023","unstructured":"Ransohoff JD, Ritter V, Purington N, Andrade K, Han S, Liu M, et al. Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nat Commun. 2023;14:2053.","journal-title":"Nat Commun"},{"key":"1839_CR318","doi-asserted-by":"publisher","first-page":"1143163","DOI":"10.3389\/fonc.2023.1143163","volume":"13","author":"Y Wang","year":"2023","unstructured":"Wang Y, Qu D, Zhang Y, Jin Y, Feng Y, Zhang H, et al. Intra-tumoral microbial community profiling and associated metabolites alterations of TNBC. Front Oncol. 2023;13:1143163.","journal-title":"Front Oncol"},{"key":"1839_CR319","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107726","volume":"215","author":"M Huang","year":"2025","unstructured":"Huang M, Zhang Y, Chen Z, Yu X, Luo S, Peng X, et al. Gut microbiota reshapes the TNBC immune microenvironment: emerging immunotherapeutic strategies. Pharmacol Res. 2025;215:107726.","journal-title":"Pharmacol Res"},{"key":"1839_CR320","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ijc.33496","volume":"149","author":"NMY Teng","year":"2021","unstructured":"Teng NMY, Price CA, McKee AM, Hall LJ, Robinson SD. Exploring the impact of gut microbiota and diet on breast cancer risk and progression. Int J Cancer. 2021;149:494\u2013504.","journal-title":"Int J Cancer"},{"key":"1839_CR321","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2306776121","volume":"121","author":"J Chen","year":"2024","unstructured":"Chen J, Liu X, Zou Y, Gong J, Ge Z, Lin X, et al. A high-fat diet promotes cancer progression by inducing gut microbiota-mediated leucine production and PMN-MDSC differentiation. Proc Natl Acad Sci U S A. 2024;121:e2306776121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1839_CR322","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.7150\/ijbs.86717","volume":"19","author":"X Shao","year":"2023","unstructured":"Shao X, Liu L, Zhou Y, Zhong K, Gu J, Hu T, et al. High-fat diet promotes colitis-associated tumorigenesis by altering gut microbial butyrate metabolism. Int J Biol Sci. 2023;19:5004\u201319.","journal-title":"Int J Biol Sci"},{"key":"1839_CR323","first-page":"0600","volume":"8","author":"Y Tang","year":"2025","unstructured":"Tang Y, Cai Q, Tian Z, Chen W, Tang H. Crosstalk between gut microbiota and cancer immunotherapy: present investigations and future perspective. Research (Washington, DC). 2025;8:0600.","journal-title":"Research (Washington, D.C.)"},{"key":"1839_CR324","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.psc.2023.04.010","volume":"46","author":"JK Penberthy","year":"2023","unstructured":"Penberthy JK, Stewart AL, Centeno CF, Penberthy DR. Psychological aspects of breast cancer. Psychiatr Clin North Am. 2023;46:551\u201370.","journal-title":"Psychiatr Clin North Am"},{"key":"1839_CR325","doi-asserted-by":"publisher","first-page":"13","DOI":"10.31887\/DCNS.2018.20.1\/ilangrollin","volume":"20","author":"I Lang-Rollin","year":"2018","unstructured":"Lang-Rollin I, Berberich G. Psycho-oncology. Dialogues Clin Neurosci. 2018;20:13\u201322.","journal-title":"Dialogues Clin Neurosci"},{"key":"1839_CR326","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1038\/s41380-020-00865-6","volume":"25","author":"X Wang","year":"2020","unstructured":"Wang X, Wang N, Zhong L, Wang S, Zheng Y, Yang B, et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: a systematic review and meta-analysis of 282,203 patients. Mol Psychiatry. 2020;25:3186\u201397.","journal-title":"Mol Psychiatry"},{"key":"1839_CR327","doi-asserted-by":"publisher","DOI":"10.2196\/57415","volume":"11","author":"F Malandrone","year":"2024","unstructured":"Malandrone F, Urru S, Berchialla P, Rossini PG, Oliva F, Bianchi S, et al. Exploring the effects of variety and amount of mindfulness practices on depression anxiety, and stress symptoms: longitudinal study on a mental health-focused ehealth system for patients with breast or prostate cancer. JMIR Mental Health. 2024;11:e57415.","journal-title":"JMIR Mental Health"},{"key":"1839_CR328","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/oncolo\/oyad164","volume":"28","author":"SLP Atkins","year":"2023","unstructured":"Atkins SLP, Greer YE, Jenkins S, Gatti-Mays ME, Houston N, Lee S, et al. Open-label phase II study of ONC201 in recurrent\/refractory metastatic breast cancer and advanced endometrial carcinoma. Oncologist. 2023;28:919-e972.","journal-title":"Oncologist"},{"key":"1839_CR329","first-page":"73","volume":"12","author":"QQ Liu","year":"2025","unstructured":"Liu QQ, Dong ZK, Wang YF, Jin WL. Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies. Mil Med Res. 2025;12:73.","journal-title":"Mil Med Res"},{"key":"1839_CR330","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12943-024-02219-0","volume":"24","author":"Q Huang","year":"2025","unstructured":"Huang Q, Hu B, Zhang P, Yuan Y, Yue S, Chen X, et al. Neuroscience of cancer: unraveling the complex interplay between the nervous system, the tumor and the tumor immune microenvironment. Mol Cancer. 2025;24:24.","journal-title":"Mol Cancer"},{"key":"1839_CR331","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1172\/JCI167725","volume":"133","author":"SY Xiong","year":"2023","unstructured":"Xiong SY, Wen HZ, Dai LM, Lou YX, Wang ZQ, Yi YL, et al. A brain-tumor neural circuit controls breast cancer progression in mice. J Clin Investigation. 2023;133:24.","journal-title":"J Clin Investigation"},{"key":"1839_CR332","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1158\/1940-6207.CAPR-22-0113","volume":"15","author":"LW Bowers","year":"2022","unstructured":"Bowers LW, Doerstling SS, Shamsunder MG, Lineberger CG, Rossi EL, Montgomery SA, et al. Reversing the genomic, epigenetic, and triple-negative breast cancer-enhancing effects of obesity. Cancer Prev Res. 2022;15:581\u201394.","journal-title":"Cancer Prev Res"},{"key":"1839_CR333","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.cmet.2024.11.004","volume":"37","author":"F Ligorio","year":"2025","unstructured":"Ligorio F, Vingiani A, Torelli T, et al. Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients. Cell Metab. 2025;37:330-344.e337.","journal-title":"Cell Metab"},{"issue":"2022","key":"1839_CR334","first-page":"300","volume":"172","author":"F Ligorio","year":"1990","unstructured":"Ligorio F, Fuc\u00e0 G, Provenzano L, Lobefaro R, Zanenga L, Vingiani A, et al. Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial. Eur J Cancer (Oxford England). 1990;172(2022):300\u201310.","journal-title":"Eur J Cancer (Oxford England)"},{"key":"1839_CR335","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1186\/s13063-020-04429-5","volume":"21","author":"Y Wang","year":"2020","unstructured":"Wang Y, Jing MX, Jiang L, Jia YF, Ying E, Cao H, et al. Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial. Trials. 2020;21:487.","journal-title":"Trials"},{"key":"1839_CR336","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/s41467-020-20743-7","volume":"12","author":"M Das","year":"2021","unstructured":"Das M, Ellies LG, Kumar D, Sauceda C, Oberg A, Gross E, et al. Time-restricted feeding normalizes hyperinsulinemia to inhibit breast cancer in obese postmenopausal mouse models. Nat Commun. 2021;12:565.","journal-title":"Nat Commun"},{"issue":"4","key":"1839_CR337","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3892\/ol.2025.14956","volume":"29","author":"Y Guo","year":"2025","unstructured":"Guo Y, Dong W, Sun D, Zhao X, Huang Z, Liu C, et al. Bacterial metabolites: Effects on the development of breast cancer and therapeutic efficacy. Oncol Letters. 2025;29(4):210.","journal-title":"Oncol Letters"},{"key":"1839_CR338","doi-asserted-by":"publisher","first-page":"5285","DOI":"10.1200\/JCO.23.00871","volume":"41","author":"T Sanft","year":"2023","unstructured":"Sanft T, Harrigan M, McGowan C, Cartmel B, Zupa M, Li FY, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol Off J Am Soc of Clin Oncol. 2023;41:5285\u201395.","journal-title":"J Clin Oncol Off J Am Soc of Clin Oncol"},{"key":"1839_CR339","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/ijc.34701","volume":"154","author":"F Ligorio","year":"2024","unstructured":"Ligorio F, Lobefaro R, Fuc\u00e0 G, et al. Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: a subanalysis of the NCT03340935 trial. Int J Cancer. 2024;154:114\u201323.","journal-title":"Int J Cancer"},{"key":"1839_CR340","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.7150\/jca.105352","volume":"16","author":"L Zhou","year":"2025","unstructured":"Zhou L, Yang Y, Luo X, Gan X, He C, Xia Y, et al. Effects of exercise intensity and time on efficacy of paclitaxel and doxorubicin and immune microenvironment in the 4T1 breast cancer model. J Cancer. 2025;16:2298\u2013311.","journal-title":"J Cancer"},{"key":"1839_CR341","doi-asserted-by":"publisher","DOI":"10.1016\/j.jshs.2025.101041","volume":"14","author":"A Mlynska","year":"2025","unstructured":"Mlynska A, Dobrovolskiene N, Suveizde K, Lukaseviciute G, Sagini K, Martin-Gracia B, et al. Exercise-induced extracellular vesicles delay tumor development by igniting inflammation in an immunologically cold triple-negative breast cancer mouse model. J Sport Health Sci. 2025;14:101041.","journal-title":"J Sport Health Sci"},{"key":"1839_CR342","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1249\/MSS.0000000000003250","volume":"55","author":"E Cho","year":"2023","unstructured":"Cho E, Stampley J, Wall R, Matthews R, Zunica E, Brown JC, et al. Acute exercise increases NK cell mitochondrial respiration and cytotoxicity against triple-negative breast cancer cells under hypoxic conditions. Med Sci Sports Exerc. 2023;55:2132\u201342.","journal-title":"Med Sci Sports Exerc"},{"key":"1839_CR343","doi-asserted-by":"publisher","first-page":"1533798","DOI":"10.3389\/fimmu.2025.1533798","volume":"16","author":"R Stagaard","year":"2025","unstructured":"Stagaard R, Jensen A, Schauer T, Bay ML, Tavanez AR, Wiels\u00f8e S, et al. Exercise boost after surgery improves survival in model of metastatic breast cancer. Front Immunol. 2025;16:1533798.","journal-title":"Front Immunol"},{"key":"1839_CR344","unstructured":"Yang Z, Wang L, Xin XU, Jie LI, Shengli HU, Ying W. Clinical effect of Shugan Jieyu San for improving liver function and alleviating depression in patients with triple negative breast cancer. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan. 2025;45:633\u2013638."},{"key":"1839_CR345","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ijpharm.2017.07.085","volume":"530","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Kennell C, Jafari M, Lee JY, Ruiz-Torres SJ, Waltz SE, et al. Sequential delivery of erlotinib and doxorubicin for enhanced triple negative breast cancer treatment using polymeric nanoparticle. Int J Pharm. 2017;530:300\u20137.","journal-title":"Int J Pharm"},{"key":"1839_CR346","doi-asserted-by":"publisher","first-page":"53654","DOI":"10.1021\/acsami.0c15089","volume":"12","author":"P Liu","year":"2020","unstructured":"Liu P, Liu X, Cheng Y, Zhong S, Shi X, Wang S, et al. Core-shell nanosystems for self-activated drug-gene combinations against triple-negative breast cancer. ACS Appl Mater Interfaces. 2020;12:53654\u201364.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1839_CR347","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jconrel.2024.06.012","volume":"371","author":"S Zheng","year":"2024","unstructured":"Zheng S, Li M, Xu W, Zhang J, Li G, Xiao H, et al. Dual-targeted nanoparticulate drug delivery systems for enhancing triple-negative breast cancer treatment. J Controll Release Off J Controll Release Soc. 2024;371:371\u201385.","journal-title":"J Controll Release Off J Controll Release Soc"},{"key":"1839_CR348","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1039\/D3BM01931D","volume":"12","author":"RJ Cavanagh","year":"2024","unstructured":"Cavanagh RJ, Monteiro PF, Moloney C, Travanut A, Mehradnia F, Taresco V, et al. Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. Biomater Sci. 2024;12:1822\u201340.","journal-title":"Biomater Sci"},{"key":"1839_CR349","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1021\/acsami.9b00704","volume":"11","author":"R Juneja","year":"2019","unstructured":"Juneja R, Lyles Z, Vadarevu H, Afonin KA, Vivero-Escoto JL. Multimodal polysilsesquioxane nanoparticles for combinatorial therapy and gene delivery in triple-negative breast cancer. ACS Appl Mater Interfaces. 2019;11:12308\u201320.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1839_CR350","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","volume":"14","author":"MM van der Lee","year":"2015","unstructured":"van der Lee MM, Groothuis PG, Ubink R, van der Vleuten MA, van Achterberg TA, Loosveld EM, et al. The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers. Mol Cancer Ther. 2015;14:692\u2013703.","journal-title":"Mol Cancer Ther"},{"key":"1839_CR351","doi-asserted-by":"crossref","unstructured":"Tolcher AW, Meric-Bernstam F, McKean M, Beerli RR, Waldmeier L, Gebleux R, Hellmann I, Chrom P, Grawunder U. NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors\u2014A phase 1\/2 clinical trial. Wolters Kluwer Health. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1108"},{"key":"1839_CR352","doi-asserted-by":"publisher","first-page":"P6","DOI":"10.1158\/1538-7445.SABCS18-P6-17-13","volume":"79","author":"KJ Hamblett","year":"2019","unstructured":"Hamblett KJ, Barnscher SD, Davies RH, Hammond PW, Hernandez A, Wickman GR, et al. Abstract P6\u201317-13: ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers. Cancer Res. 2019;79:P6-17.","journal-title":"Cancer Res"},{"key":"1839_CR353","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1158\/1538-7445.AM2018-3914","volume":"78","author":"KJ Hamblett","year":"2018","unstructured":"Hamblett KJ, Hammond PW, Barnscher SD, Fung VK, Davies RH, Wickman GR, et al. ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers. Cancer Res. 2018;78:3914.","journal-title":"Cancer Res"},{"key":"1839_CR354","doi-asserted-by":"crossref","unstructured":"Hu X, Zhang J, Liu R, Gao S, Qing Y, Yi S, Yuan J, Chen H, Fan B, Zheng H. Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. Wolters Kluwer Health. 2021.","DOI":"10.1200\/JCO.2021.39.15_suppl.1024"},{"key":"1839_CR355","doi-asserted-by":"crossref","unstructured":"Park YH, Ahn HK, Kim J-Y, Ahn JS, Im Y-H, Kim S-H, Lee S, Chung H-S, Park SJ. First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer. Am Soc Clin Oncol. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.3551"},{"key":"1839_CR356","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2019.12.037","volume":"473","author":"M Barok","year":"2020","unstructured":"Barok M, Le Joncour V, Martins A, Isola J, Salmikangas M, Laakkonen P, et al. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. Cancer Lett. 2020;473:156\u201363.","journal-title":"Cancer Lett"},{"key":"1839_CR357","doi-asserted-by":"crossref","unstructured":"Liu Y, Lian W, Zhao X, Diao Y, Xu J, Xiao L, Qing Y, Xue T, Wang J. SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable\/metastatic solid tumors who are refractory to available standard therapies. Am Soc Clin Oncol. 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3659"},{"key":"1839_CR358","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1538-7445.AM2018-833","volume":"78","author":"LL Sharp","year":"2018","unstructured":"Sharp LL, Chang C, Frey G, Wang J, Liu H, Xing C, et al. Anti-tumor efficacy of BA3021, a novel conditionally active biologic (CAB) anti-ROR2 ADC. Cancer Res. 2018;78:833.","journal-title":"Cancer Res"},{"key":"1839_CR359","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab Vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res. 2016;76:3003\u201313.","journal-title":"Cancer Res"},{"key":"1839_CR360","doi-asserted-by":"publisher","DOI":"10.1177\/11769351221076062","volume":"21","author":"T Hirahata","year":"2022","unstructured":"Hirahata T, Ul Quraish R, Quraish AU, Ul Quraish S, Naz M, Razzaq MA. Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer. Cancer Inform. 2022;21:11769351221076062.","journal-title":"Cancer Inform"},{"key":"1839_CR361","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"1839_CR362","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.15252\/emmm.201404913","volume":"7","author":"E Olsson","year":"2015","unstructured":"Olsson E, Winter C, George A, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7:1034\u201347.","journal-title":"EMBO Mol Med"},{"key":"1839_CR363","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","volume":"6","author":"M Radovich","year":"2020","unstructured":"Radovich M, Jiang G, Hancock BA, et al. Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the bre12-158 randomized clinical trial. JAMA Oncol. 2020;6:1410\u20135.","journal-title":"JAMA Oncol"},{"key":"1839_CR364","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102914","volume":"58","author":"AA Davis","year":"2020","unstructured":"Davis AA, Jacob S, Gerratana L, Shah AN, Wehbe F, Katam N, et al. Landscape of circulating tumour DNA in metastatic breast cancer. EBioMedicine. 2020;58:102914.","journal-title":"EBioMedicine"},{"key":"1839_CR365","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179952","author":"AJA Freitas","year":"2022","unstructured":"Freitas AJA, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, et al. Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23179952.","journal-title":"Int J Mol Sci"},{"key":"1839_CR366","doi-asserted-by":"publisher","first-page":"1607960","DOI":"10.3389\/fonc.2025.1607960","volume":"15","author":"J Sheng","year":"2025","unstructured":"Sheng J, Zong X. Liquid biopsy in TNBC: significance in diagnostics, prediction, and treatment monitoring. Front Oncol. 2025;15:1607960.","journal-title":"Front Oncol"},{"key":"1839_CR367","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23147843","author":"S Addanki","year":"2022","unstructured":"Addanki S, Meas S, Sarli VN, Singh B, Lucci A. Applications of circulating tumor cells and circulating tumor dna in precision oncology for breast cancers. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23147843.","journal-title":"Int J Mol Sci"},{"key":"1839_CR368","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/cge.13514","volume":"95","author":"S Alimirzaie","year":"2019","unstructured":"Alimirzaie S, Bagherzadeh M, Akbari MR. Liquid biopsy in breast cancer: a comprehensive review. Clin Genet. 2019;95:643\u201360.","journal-title":"Clin Genet"},{"key":"1839_CR369","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/path.6155","volume":"260","author":"J Thagaard","year":"2023","unstructured":"Thagaard J, Broeckx G, Page DB, et al. Specht stovgaard, pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group on breast cancer. J Pathol. 2023;260:498\u2013513.","journal-title":"J Pathol"},{"key":"1839_CR370","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103492","volume":"70","author":"P Sun","year":"2021","unstructured":"Sun P, He J, Chao X, Chen K, Xu Y, Huang Q, et al. A computational tumor-infiltrating lymphocyte assessment method comparable with visual reporting guidelines for triple-negative breast cancer. EBioMedicine. 2021;70:103492.","journal-title":"EBioMedicine"},{"key":"1839_CR371","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103520","volume":"70","author":"B Acs","year":"2021","unstructured":"Acs B, Salgado R, Hartman J. What do we still need to learn on digitally assessed biomarkers? EBioMedicine. 2021;70:103520.","journal-title":"EBioMedicine"},{"key":"1839_CR372","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41422-022-00614-0","volume":"32","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y, et al. Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022;32:477\u201390.","journal-title":"Cell Res"},{"key":"1839_CR373","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15080514","author":"A Elguoshy","year":"2025","unstructured":"Elguoshy A, Zedan H, Saito S. Machine learning-driven insights in cancer metabolomics: from subtyping to biomarker discovery and prognostic modeling. Metabolites. 2025. https:\/\/doi.org\/10.3390\/metabo15080514.","journal-title":"Metabolites"},{"issue":"10","key":"1839_CR374","doi-asserted-by":"publisher","first-page":"e0311810","DOI":"10.1371\/journal.pone.0311810","volume":"19","author":"NK Anh","year":"2024","unstructured":"Anh NK, Lee A, Phat NK, Yen NT, Thu NQ, Tien NT, et al. Combining metabolomics and machine learning to discover biomarkers for early-stage breast cancer diagnosis. PLoS One. 2024;19(10):e0311810.","journal-title":"PLoS One"},{"key":"1839_CR375","doi-asserted-by":"publisher","first-page":"1544348","DOI":"10.3389\/fimmu.2025.1544348","volume":"16","author":"F Li","year":"2025","unstructured":"Li F, Jin C, Pan Y, Zhang Z, Wang L, Deng J, et al. Construction of a stromal cell-related prognostic signature based on a 101-combination machine learning framework for predicting prognosis and immunotherapy response in triple-negative breast cancer. Front Immunol. 2025;16:1544348.","journal-title":"Front Immunol"},{"key":"1839_CR376","first-page":"523","volume":"17","author":"A Agelidis","year":"2025","unstructured":"Agelidis A, Ter-Zakarian A, Jaloudi M. Triple-negative breast cancer on the rise: breakthroughs and beyond. Breast Cancer (Dove Medical Press). 2025;17:523\u20139.","journal-title":"Breast Cancer (Dove Medical Press)"},{"key":"1839_CR377","first-page":"130","volume":"31","author":"B Sz\u00e9kely","year":"2017","unstructured":"Sz\u00e9kely B, Silber AL, Pusztai L. New therapeutic strategies for triple-negative breast cancer. Oncology (Williston Park, NY). 2017;31:130\u20137.","journal-title":"Oncology (Williston Park, N.Y.)"},{"key":"1839_CR378","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11864-017-0506-9","volume":"18","author":"A La Belle","year":"2017","unstructured":"La Belle A, Khatib J, Schiemann WP, Vinayak S. Role of platinum in early-stage triple-negative breast cancer. Curr Treat Options Oncol. 2017;18:68.","journal-title":"Curr Treat Options Oncol"},{"key":"1839_CR379","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, et al. Esserman, effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6:676\u201384.","journal-title":"JAMA Oncol"},{"key":"1839_CR380","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, de Graaf M, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024;30:3223\u201335.","journal-title":"Nat Med"},{"key":"1839_CR381","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13058-024-01883-w","volume":"26","author":"BV Sinn","year":"2024","unstructured":"Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, et al. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res BCR. 2024;26:138.","journal-title":"Breast Cancer Res BCR"},{"key":"1839_CR382","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","volume":"621","author":"XQ Wang","year":"2023","unstructured":"Wang XQ, Danenberg E, Huang CS, et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature. 2023;621:868\u201376.","journal-title":"Nature"},{"key":"1839_CR383","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101825","volume":"5","author":"C Denkert","year":"2024","unstructured":"Denkert C, Schneeweiss A, Rey J, et al. Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer. Cell Rep Med. 2024;5:101825.","journal-title":"Cell Rep Med"},{"key":"1839_CR384","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41422-023-00795-2","volume":"33","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zhu XZ, Xiao Y, Wu SY, Zuo WJ, Yu Q, et al. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial. Cell Res. 2023;33:389\u2013402.","journal-title":"Cell Res"},{"key":"1839_CR385","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.annonc.2020.09.004","volume":"31","author":"K Kalinsky","year":"2020","unstructured":"Kalinsky K, Diamond JR, Vahdat LT, Tolaney SM, Juric D, O\u2019Shaughnessy J, et al. Sacituzumab govitecan in previously treated hormone receptor-positive\/HER2-negative metastatic breast cancer: final results from a phase I\/II, single-arm, basket trial. Annals Oncol Off J Eur Soc Med Oncol. 2020;31:1709\u201318.","journal-title":"Annals Oncol Off J Eur Soc Med Oncol"},{"key":"1839_CR386","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12943-025-02342-6","volume":"24","author":"QS Chen","year":"2025","unstructured":"Chen QS, Cai RZ, Wang Y, Liang GH, Zhang KM, Yang XY, et al. Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-targetable vulnerabilities. Mol Cancer. 2025;24:141.","journal-title":"Mol Cancer"},{"issue":"1","key":"1839_CR387","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-025-02070-1","volume":"27","author":"RA Leon-Ferre","year":"2025","unstructured":"Leon-Ferre RA, Dimitroff K, Yau C, et al. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. Breast Cancer Res. 2025;27(1):115.","journal-title":"Breast Cancer Res"},{"key":"1839_CR388","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03267-1","author":"RA Shatsky","year":"2024","unstructured":"Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, et al. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03267-1.","journal-title":"Nat Med"},{"key":"1839_CR389","doi-asserted-by":"crossref","unstructured":"Oberstein PE, Pelster M, Culm K, Chamberlain Santos V, Koustenis A, Mockbee CM, Youssoufian H, Krauss JC. ONCX-NAV-G201: A phase 2 basket study of navicixizumab monotherapy or in combination with chemotherapy in patients with select advanced solid tumors\u2014Colorectal Cancer Cohort (trial in progress). 2023:TPS263.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS263"},{"key":"1839_CR390","doi-asserted-by":"crossref","unstructured":"C. Rojas, F. Eskens, F. Ghiringhelli et al. Vibostolimab coformulated with pembrolizumab (vibo\/pembro) for previously treated advanced mismatch repair-deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study. 2024: 5502.","DOI":"10.1200\/JCO.2024.42.16_suppl.5502"},{"key":"1839_CR391","doi-asserted-by":"crossref","unstructured":"Winer IS, Barve MA, Shah S, Sharma M, Marsolais C, Demeule M, Daigle K, Douglas LM, Meric-Bernstam F. Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC). 2024:3081.","DOI":"10.1200\/JCO.2024.42.16_suppl.3081"},{"key":"1839_CR392","doi-asserted-by":"crossref","unstructured":"Park H, Bendell JC, Messersmith WA, Rasco DW, De Bono JS, Strickler JH, Zhou L, Carter LL, Bruey JM, Li J, Raghupathi K, Dupont J, Chaney MF, Park W Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36). 2021:2505.","DOI":"10.1200\/JCO.2021.39.15_suppl.2505"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01839-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:02:48Z","timestamp":1787774568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01839-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":392,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1839"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01839-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"4 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"57"}}